川瀬 篤史 (カワセ アツシ)

  • 薬学部 医療薬学科 准教授
Last Updated :2024/02/01

コミュニケーション情報 byコメンテータガイド

  • コメント

    薬物の作用や副作用を決定する因子のひとつである薬物体内動態(吸収・分布・代謝・排泄)について。薬物体内動態を制御することで薬の効果を最大限に得るドラッグデリバリーシステムについて。

研究者情報

学位

  • 博士(薬学)(2005年03月 京都大学)

ホームページURL

J-Global ID

研究キーワード

  • トランスポーター   肝障害   炎症   ERストレス   エクソソーム   

現在の研究分野(キーワード)

    薬物の作用や副作用を決定する因子のひとつである薬物体内動態(吸収・分布・代謝・排泄)について。薬物体内動態を制御することで薬の効果を最大限に得るドラッグデリバリーシステムについて。

研究分野

  • ライフサイエンス / 医療薬学 / 薬物動態学

所属学協会

  • 日本毒性学会   日本プロテオーム学会   日本薬物動態学会   日本薬学会   日本薬剤学会   

研究活動情報

論文

  • Atsushi Kawase; Kota Irie; Naoya Matsuda; Yuzuki Takai; Hiroaki Shimada; Masahiro Iwaki
    Molecular medicine reports 26 5 2022年11月 
    The role of high mobility group box 1 (HMGB1) in the regulation of efflux transporters in the liver and kidney remains unclear, although it has been reported that HMGB1 can increase P‑glycoprotein (P‑gp) expression in the brain. The present study aimed to clarify the involvement of HMGB1 in the regulation of P‑gp expression in the liver and kidney of mice with lipopolysaccharide (LPS)‑induced inflammation. Mice were treated with LPS or LPS + glycyrrhizin (GL); GL is as an HMGB1 inhibitor. Subsequently, the expression levels of transporters, such as P‑gp, and HMGB1 receptors, such as toll‑like receptor (TLR)4 and receptor for advanced glycation end‑products (RAGE), were determined by quantitative PCR and LC‑MS/MS‑based targeted proteomics. For the in vitro study, HepG2 and KMRC‑1 cells were used, as was a co‑culture of KMRC‑1 and differentiated THP‑1 cells. The mRNA and protein expression levels of Mdr1a and Tlr4 in the kidneys of LPS + GL‑treated mice were significantly decreased compared with those in LPS mice. The results indicated that HMGB1 had little effect on the expression of Mdr1a and Tlr4 in the liver, since there was little change in of Mdr1a and Mdr1b expression between the LPS and LPS + GL‑treated mice. Notably, regarding MDR1 mRNA expression, KMRC‑1 cells were more responsive to LPS than HepG2 cells, and KMRC‑1 cells treated with LPS exhibited increased levels compared with control KMRC‑1 cells. In differentiated THP‑1 cells, LPS treatment decreased the mRNA expression levels of TLR4, whereas they were restored to control levels by HMGB1. In conclusion, HMGB1 in the plasma and TLR4 in macrophages may be involved in the regulation of P‑gp expression in the kidneys of inflamed mice.
  • Hiroyuki Ikuta; Hiroaki Shimada; Kenjiro Sakamoto; Rena Nakamura; Atsushi Kawase; Masahiro Iwaki
    Xenobiotica; the fate of foreign compounds in biological systems 52 7 1 - 28 2022年10月 
    Acyl glucuronides (AGs) are known as one of the causes of idiosyncratic drug toxicity (IDT). Although AGs can be enzymatically hydrolysed by β-glucuronidase and esterase, much information on their characteristics and species differences is lacking. This study was aimed to clarify species differences in AG hydrolysis between human and rat liver microsomes (HLM and RLM).To evaluate the AG hydrolysis profile, and the contribution of β-glucuronidase and esterase towards AG hydrolysis in HLM and RLM, nonsteroidal anti-inflammatory drugs (NSAIDs) were used. AGs were incubated with 0.1 M Tris-HCl buffer (pH 7.4) and 0.3 mg/mL HLM or RLM in the absence or presence of β-glucuronidase inhibitor, D-saccharic acid 1,4-lactone (D-SL) and esterase inhibitor, phenylmethylsulfonyl fluoride (PMSF).AGs of zomepirac (ZOM-AG), mefenamic acid (MEF-AG), and etodolac (ETO-AG) showed significantly higher AG hydrolysis rates in RLM than in HLM. Esterases were found to serve as AG hydrolases dominantly in HLM, whereas both esterases and β-glucuronidase equally contribute to AG hydrolysis in RLM. However, MEF-AG and ETO-AG were hydrolysed only by β-glucuronidase.We demonstrated for the first time that the activity of AG hydrolases towards NSAID-AGs differs between humans and rats.
  • Atsushi Kawase; Ouka Takashima; Satsuki Tanaka; Hiroaki Shimada; Masahiro Iwaki
    International journal of molecular sciences 23 15 2022年08月 
    Non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac (DIC) frequently induce drug-induced liver injury (DILI). It is unclear whether macrophages such as M1 and M2 participate in NSAID-associated DILI; elucidating this relationship could lead to a better understanding of the detailed mechanism of DILI. We co-cultured human hepatoma HepG2 cells with M1 or M2 derived from human monocytic leukemia THP-1 cells to examine the roles of M1 and M2 in DIC-induced cytotoxicity. DIC was added to the direct or indirect co-cultures of HepG2 cells with M1 or M2 (HepG2/M1 or HepG2/M2, respectively) at cell ratios of (1:0, 1:0.1, 1:0.4, and 1:1). In both direct and indirect HepG2/M2 co-cultures (1:0.4), there was lower lactate dehydrogenase release compared with HepG2/M1 co-cultures. Other NSAIDs as well as DIC showed similar protective effects of DIC-induced cytotoxicity. There were only slight differences in mRNA levels of apoptosis- and endoplasmic reticulum stress-associated factors between M1 and M2 after DIC treatment, suggesting that other factors determined the protective effects of M2 on DIC-induced cytotoxicity. Levels of high mobility group box 1 (HMGB1) in the medium and the mRNA expression levels of HMGB1 receptors were different between M1 and M2 after DIC treatment. Increased HMGB1 concentrations and expression of toll-like receptor 2 mRNA in M1 were observed compared with M2 after DIC treatment. In conclusion, these results suggested that the HMGB1/TLR2 signaling axis can be suppressed in M2 but not M1, leading to the different roles of M1 and M2 in NSAID-induced cytotoxicity.
  • Atsushi Kawase; Momoko Hatanaka; Naoya Matsuda; Hiroaki Shimada; Masahiro Iwaki
    International journal of molecular sciences 23 15 2022年08月 
    SLC25A39/40, involved in mitochondrial GSH (mGSH) import from the cytoplasm, is essential for protection against oxidative stress and mitochondrial dysfunction. We examined the effects of cholestasis, through bile duct ligation (BDL) and lipopolysaccharide (LPS)-induced inflammation in mice, on Slc25a39/40 expression. Additionally, we used human clear cell renal carcinoma (KMRC-1) cells to elucidate the mechanism of regulation of SLC25A39/40 expression in the kidneys after LPS treatment. BDL resulted in a decrease in Slc25a39 mRNA in the liver and a decrease in Slc25a39/40 mRNA and protein in the kidneys. Consequently, there was a significant decrease in mGSH levels in the kidneys of BDL mice compared with those in sham mice. LPS treatment resulted in increased Slc25a40 expression in the kidneys. In KMRC-1 cells, the combination treatment of LPS-RS or FPS-ZM1 with LPS suppressed the LPS-induced increase in SLC25A40, suggesting that SLC25A40 expression could be regulated by the signaling pathway via toll-like receptor 4 and the receptor for advanced glycation end products, respectively. Our findings contribute to understanding the role of mGSH in the maintenance of the mitochondrial redox state. To the best of our knowledge, this is the first study that demonstrates the changes in Slc25a39/40 expression in mice with cholestasis-associated renal injury and LPS-induced inflammation.
  • Atsushi Kawase; Rio Yamashita; Tsubasa Yoshizato; Mashiro Yoshikawa; Hiroaki Shimada; Masahiro Iwaki
    International journal of molecular sciences 23 9 2022年04月 
    A reactive metabolite of nonsteroidal anti-inflammatory drugs (NSAIDs), acyl-β-D-glucuronide (AG), covalently binds to endogenous proteins. The covalent adduct formation of NSAIDs-AG may lead to the dysfunction of target proteins. Therefore, it is important to clarify the detailed characterization of the formation of covalent protein adducts of NSAID-AG. UDP-glucuronosyltransferase (UGT) catalyzes the conversion of NSAIDs to NSAIDs-AG. The aim of this study was to perform a quantitative analysis of the covalent adduct formation of NSAIDs-AG with UGT. Diclofenac-AG and ketoprofen-AG formed covalent adducts with organelle proteins. Next, the number of covalent adducts formed between NSAIDs-AG and UGT isoforms (UGT1A1, UGT1A9, UGT2B4, and UGT2B9) was determined. The capacity of diclofenac-AG to form covalent adducts with UGT1A9 or UGT2B7 was approximately 10 times higher than that of mefenamic acid-AG. The amounts of covalent adducts of AG of propionic acid derivative NSAIDs with UGT2B were higher than those with UGT1A. Stereoselectivity was observed upon covalent binding to UGT. A significant negative correlation between the half-lives of NSAIDs-AG in phosphate buffers and the amount of covalent adduct with UGT2B7 was observed, suggesting the more labile NSAID-AG forms higher irreversible bindings to UGT. This report provides comprehensive information on the covalent adduct formation of NSAIDs-AGs with UGT.
  • Relationship between the risk of idiosyncratic drug toxicity and formation and degradation profiles of acyl-glucuronide metabolites of nonsteroidal anti-inflammatory drugs in rat liver microsomes
    Shimada H; Ikuta H; Kumazawa K; Nomi M; Shiojiri M; Kawase A; Iwaki M
    Eur J Pharm Sci 2022年04月 [査読有り]
  • Ilex latifolia葉抽出物の食後血糖上昇抑制作用
    笹井 剛一; 島田 紘明; 上野 省一; 川瀬 篤史; 森川 敏生; 岩城 正宏
    日本薬学会年会要旨集 142年会 27T - pm06S (公社)日本薬学会 2022年03月
  • Ilex latifolia葉抽出物の食後血糖上昇抑制作用
    笹井 剛一; 島田 紘明; 上野 省一; 川瀬 篤史; 森川 敏生; 岩城 正宏
    日本薬学会年会要旨集 142年会 27T - pm06S (公社)日本薬学会 2022年03月
  • Ken-Ichi Oba; Hiroaki Shimada; Ryota Hashimoto; Atsushi Kawase; Takeo Nakanishi; Masahiro Iwaki
    Endocrine regulations 56 1 22 - 30 2022年02月 
    Objective. Carbamazepine (CBZ), a widely used antiepileptic drug, is one major cause of the idiosyncratic liver injury along with immune reactions. Conversely, prostaglandin E2 (PGE2) demonstrates a hepatoprotective effect by regulating immune reactions and promoting liver repair in various types of liver injury. However, the amount of hepatic PGE2 during CBZ-induced liver injury remains elusive. In this study, we aimed to evaluate the hepatic PGE2 levels during CBZ-induced liver injury using a mouse model. Methods. Mice were orally administered with CBZ at a dose of 400 mg/kg for 4 days, and 800 mg/kg on the 5th day. Results. Plasma alanine transaminase (ALT) level increased in some of mice 24 h after the last CBZ administration. Although median value of hepatic PGE2 amount in the CBZ-treated mice showed same extent as vehicle-treated control mice, it exhibited significant elevated level in mice with severe liver injury presented by a plasma ALT level >1000 IU/L. According to these results, mice had a plasma ALT level >1000 IU/L were defined as responders and the others as non-responders in this study. Even though, the hepatic PGE2 levels increased in responders, the hepatic expression and enzyme activity related to PGE2 production were not upregulated when compared with vehicle-treated control mice. However, the hepatic 15-hydroxyprostaglandin dehydrogenase (15-PGDH) expression and activity decreased significantly in responders when compared with control mice. Conclusions. These results indicate that elevated hepatic PGE2 levels can be attributed to the downregulation of 15-PGDH expression under CBZ-induced liver injury.
  • Yoshihito Kasanami; Chihiro Ishikawa; Takahiro Kino; Momoka Chonan; Naoki Toyooka; Yasuhiro Takashima; Yuriko Iba; Fumiko Sekiguchi; Maho Tsubota; Tsuyako Ohkubo; Shigeru Yoshida; Atsushi Kawase; Takuya Okada; Atsufumi Kawabata
    European Journal of Medicinal Chemistry 243 114716 - 114716 2022年 [査読有り]
     
    T-type Ca2+ channels (T-channels), particularly Cav3.2 and Cav3.1 isoforms, are promising targets for treating various diseases including intractable pain. Given the potent inhibitory activity of pimozide, an antipsychotic, against T-channels, we conducted structure-activity relationship studies of pimozide derivatives, and identified several compounds including 3a, 3s, and 4 that had potency comparable to that of pimozide in inhibiting T-channels, but little binding affinity to dopamine D2 receptors. The introduction of a phenylbutyl group on the benzoimidazole nuclei of pimozide was considered a key structural modification to reduce the binding affinity to D2 receptors. Those pimozide derivatives potently suppressed T-channel-dependent somatic and visceral pain in mice, without causing any motor dysfunctions attributable to D2 receptor blockade, including catalepsy. The present study thus provides an avenue to develop novel selective T-channel inhibitors available for pain management via the structural modification of existing medicines.
  • Kawase A; Mukai H; Tateishi S; Kuroda S; Kazaoka A; Satoh R; Shimada H; Sugiura R; Iwaki M
    J Pharmacol Exp Ther 379 1 53 - 63 2021年 [査読有り]
     
    In receptor-type transcription factors-mediated cytochrome P450 (P450) induction, few studies have attempted to clarify the roles of protein kinase N (PKN) in the transcriptional regulation of P450s. This study aimed to examine the involvement of PKN in the transcriptional regulation of P450s by receptor-type transcription factors, including the aryl hydrocarbon receptor, constitutive androstane receptor (CAR), and pregnane X receptor. The mRNA and protein levels and metabolic activity of P450s in the livers of wild-type (WT) and double-mutant (D) mice harboring both PKN1 kinase-negative knock-in and PKN3 knockout mutations [PKN1 T778A/T778A; PKN3 -/-] were determined after treatment with activators for receptor-type transcription factors. mRNA and protein levels and metabolic activity of CYP2B10 were significantly higher in D mice treated with the CAR activator phenobarbital (PB) but not with 1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene compared with WT mice. We examined the CAR-dependent pathway regulated by PKN after PB treatment because the extent of CYP2B10 induction in WT and D mice was notably different in response to treatment with different CAR activators. The mRNA levels of Cyp2b10 in primary hepatocytes from WT and D mice treated with PB alone or in combination with Src kinase inhibitor 1 (SKI-1) or U0126 (a mitogen-activated protein kinase inhibitor) were evaluated. Treatment of hepatocytes from D mice with the combination of PB with U0126 but not SKI-1 significantly increased the mRNA levels of Cyp2b10 compared with those from the corresponding WT mice. These findings suggest that PKN may have inhibitory effects on the Src-receptor for activated C kinase 1 (RACK1) pathway in the CAR-mediated induction of Cyp2b10 in mice livers. SIGNIFICANCE STATEMENT: This is the first report of involvement of PKN in the transcriptional regulation of P450s. The elucidation of mechanisms responsible for induction of P450s could help optimize the pharmacotherapy and improve drug development. We examined whether the mRNA and protein levels and activities of P450s were altered in double-mutant mice harboring both PKN1 kinase-negative knock-in and PKN3 knockout mutations. PKN1/3 negatively regulates CAR-mediated induction of Cyp2b10 through phosphorylation of a signaling molecule in the Src-RACK1 pathway.
  • Increased brain penetration of diphenhydramine and memantine in rats with adjuvant-induced arthritis
    Kawase A; Kazaoka A; Shimada H; Iwaki M
    Brain Res 2021年 [査読有り]
  • NHERF1/EBP50 as a target for modulation of MRP function in HepG2 cells
    Kawase A; Hirosoko M; Sugihara Y; Koyama Y; Fukae A; Shimada H; Iwaki M
    Pharmaceuticals 2021年 [査読有り]
  • Kawase A; Chuma T; Irie K; Kazaoka A; Kakuno A; Matsuda N; Shimada H; Iwaki M
    Brain Behav Immun Health 10 100188 - 100188 2021年 [査読有り]
     
    Uptake transporters in brain microvascular endothelial cells (BMECs) are involved in the penetration of basic (cationic) drugs such as diphenhydramine (DPHM) into the brain. Lipopolysaccharide (LPS)-induced inflammation alters the expression levels and activities of uptake transporters, which change the penetration of DPHM into the brain. A brain microdialysis study showed that the unbound brain-to-plasma partition coefficient (K p,uu,brain) for DPHM in LPS rats was approximately two times higher than that in control rats. The transcellular transport of DPHM to BMECs was increased when BMECs were cultured with serum from LPS rats. Compared with control rats or BMECs, the brain uptake of DPHM in LPS rats was increased and the intracellular accumulation of DPHM was increased under a high intracellular pH in BMECs from LPS rats, respectively. Treatment of BMECs with transporter inhibitors or inflammatory cytokines had little impact on the intracellular accumulation of DPHM in BMECs. This study suggests that LPS-induced inflammation promotes unidentified proton-coupled organic cation (H+/OC) antiporters that improve the penetration of DPHM into rat brain via the blood-brain barrier.
  • マウスにおけるシトクロムP450誘導過程におけるプロテインキナーゼNファミリーの役割
    川瀬 篤史; 向井 秀幸; 立石 駿介; 黒田 真太郎; 松田 尚也; 佐藤 亮介; 島田 紘明; 杉浦 麗子; 岩城 正宏
    日本薬学会年会要旨集 140年会 27X - pm02 (公社)日本薬学会 2020年03月
  • Hiroaki Shimada; Ryota Hashimoto; Aya Aoki; Saya Yamada; Ken-Ichi Oba; Atsushi Kawase; Takeo Nakanishi; Masahiro Iwaki
    Prostaglandins, leukotrienes, and essential fatty acids 155 102081 - 102081 2020年02月 [査読有り]
     
    Prostaglandin E2 (PGE2) exhibits hepatoprotective effects against various types of liver injury. However, there is little information on the disposition of endogenous PGE2 during liver injury. In the present study, we attempted to elucidate the mechanism involved in regulating PGE2 distribution during liver injury. Carbon tetrachloride (CCl4) was used to establish a liver injury mouse model. PGE2 was measured by LC-MS/MS. The plasma and hepatic PGE2 levels were significantly increased at 6 to 48 h after CCl4 treatment. The ratio of plasma levels of 13,14-dihydro-15-ketoPGE2 (PGEM), a major PGE2 metabolite, to PGE2 decreased significantly after CCl4 treatment. PGE2 synthesis and expression of enzymes related to PGE2 production were not induced, while the activity and mRNA expression of 15-prostaglandin dehydrogenase (15-PGDH/Hpgd), a major enzyme for PGE2 inactivation, decreased significantly in the liver of CCl4-treated mice compared to that of vehicle-treated control. The plasma and hepatic PGE2 levels were negatively correlated with the hepatic mRNA expression levels of Hpgd. Although the mRNA expression of organic anion transporting polypeptide 2A1 (OATP2A1/Slco2a1), a major PGE2 transporter, was upregulated, other hepatic OATPs decreased significantly at 24 h after CCl4 treatment. Immunohistochemical analysis indicated that 15-PGDH was mainly expressed in endothelial cells and that OATP2A1 was expressed at least in endothelial cells and Kupffer cells in the liver. These results suggest that the decreased 15-PGDH expression in hepatic endothelial cells is the principal mechanism for the increase in hepatic and plasma PGE2 levels due to the CCl4-induced liver injury.
  • Kawase A; Nakasaka, M; Bando H; Yasuda S; Shimada H; Iwaki M
    Inflammation 43 1 85 - 94 2020年 [査読有り]
     
    Scaffold proteins such as radixin help to modulate the plasma membrane localization and transport activity of the multidrug resistance-associated protein 2 (MRP2/ABCC2) and P-glycoprotein (P-gp/ABCB1) efflux transporters in the liver. We examined changes in radixin expression and interaction with efflux transporters in adjuvant-induced arthritic (AA) rats, an animal model of rheumatoid arthritis, as well as in human liver cancer (HepG2) cells because inflammation affects drug pharmacokinetics via the efflux transporters. The expression levels of radixin and phosphorylated radixin (p-radixin) were measured 24 h after treatment with inflammatory cytokines comprising tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 or sodium nitroprusside (SNP; a nitric oxide donor). The protein levels of radixin, MRP2, and P-gp in the rat liver were next examined. We also investigated whether inflammation affected the formation of complexes between radixin and MRP2 or P-gp. The mRNA and protein levels of radixin in HepG2 cells were significantly decreased by TNF-α treatment, while minimal changes were observed after treatment with IL-1β, IL-6 or SNP. TNF-α also significantly decreased the protein levels of p-radixin, suggesting that TNF-α inhibited the activation of radixin and thereby reduced the activity of the efflux transporters. Complex formation of radixin with MRP2 and P-gp was significantly decreased in AA rats but this was reversed by prednisolone and dexamethasone treatment, indicating that decreased interactions of radixin with MRP2 and P-gp likely occur during liver inflammation. These data suggest that liver inflammation reduces radixin function by decreasing its interactions with MRP2 and P-gp.
  • Uno T; Wada K; Hosomi K; Matsuda S; Ikura MM; Takenaka H; Terakawa N; Oita A; Yokoyama S; Kawase A; Takada M
    European journal of clinical pharmacology 76 1 117 - 125 2020年01月 [査読有り]
     
    PURPOSE: This study investigated the effects of clotrimazole troche on the risk of transplant rejection and the pharmacokinetics of tacrolimus. METHODS: The data mining approach was used to investigate whether the use of clotrimazole increased the risk of transplant rejection in patients receiving tacrolimus therapy. Patient data were acquired from the US Food and Drug Administration's Adverse Event Reporting System (FAERS) from the first quarter of 2004 to the end of 2017. Next, we retrospectively investigated the effect of clotrimazole troche on tacrolimus pharmacokinetics in seven patients who underwent heart transplantation between March and December 2017. RESULTS: The FAERS subset data indicated a significant association between transplant rejection and tacrolimus with clotrimazole [reporting odds ratio 1.92, 95% two-sided confidence interval (95% CI) 1.43-2.58, information component 0.81, 95% CI 0.40-1.23]. The pharmacokinetic study demonstrated a significant correlation between trough concentration (C0) and area under the concentration-time curve of tacrolimus after discontinuation of clotrimazole (R2 = 0.60, P < 0.05) but not before its discontinuation. Furthermore, the median clearance/bioavailability of tacrolimus after discontinuation of clotrimazole was 2.2-fold greater than that before its discontinuation (0.27 vs. 0.59 L/h/kg, P < 0.05). The median C0 decreased from 10.7 ng/mL on the day after discontinuation of clotrimazole to 6.5 ng/mL at 1 day and 5.3 ng/mL at 2 days after its discontinuation. CONCLUSION: Immediate dose adjustments of tacrolimus may be beneficial to avoid transplant rejection when clotrimazole troche is added or discontinued.
  • Shimada, Hiroaki; Kuma, Chiaki; Iseri, Taichi; Matsumura, Shin-ichi; Kawase, Atsushi; Matsuura, Masayoshi; Iwaki, Masahiro
    NATURAL PRODUCT COMMUNICATIONS 14 10 2019年10月 [査読有り]
     
    The tea of Ocimum gratissimum (OG) leaves has been commonly consumed by people living in Ishigaki Island, Okinawa prefecture, Japan, and is considered to be effective for improving diabetes mellitus. In this study, we aimed to clarify the inhibitory potential of OG leaves extract (OG-ext) on gastrointestinal glucose absorption and to provide theoretical evidence for the anti-hyperglycemic effect of OG-ext. The increase of blood glucose after oral administration of alpha-starch and glucose in mice was suppressed by co-administration of OG-ext. An in vitro enzymatic assay suggested that amylase and maltase were inhibited weakly by the addition of OG-ext. In Caco-2 cells, a human intestinal epithelial model, the sodium-dependent glucose transporter (SGLT) 1-mediated uptake of fluorescence glucose analog was inhibited significantly by the addition of OG-ext in a concentration-dependent manner. These results indicate that the inhibitory effect on SGLT1 is one of the mechanisms of the anti-hyperglycemic effect of the tea of OG leaves.
  • Takaya Uno; Kyoichi Wada; Sachi Matsuda; Megumi Ikura; Hiromi Takenaka; Nobue Terakawa; Akira Oita; Satoshi Yokoyama; Atsushi Kawase; Kouichi Hosomi; Mitsutaka Takada
    British journal of clinical pharmacology 85 9 2176 - 2178 2019年09月 [査読有り]
  • Decrease in Multidrug Resistance-associated Protein 2 Activities by Knockdown of Phosphatidylinositol 4-phosphate 5-kinase in Hepatocytes and Cancer Cells
    Atsushi Kawase; Yuta Inoue; Miho Hirosoko; Yuka Sugihara; Hiroaki Shimada; Masahiro Iwaki
    Journal of Pharmacy & Pharmaceutical Sciences 2019年 [査読有り]
  • Atsushi Kawase; Akira Kazaoka; Rei Yamamoto; Risa Minakata; Hiroaki Shimada; Masahiro Iwaki
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 22 1 457 - 465 2019年 [査読有り]
     
    PURPOSE: Bile duct ligation (BDL) in experimental animals is widely used as an animal model of liver cholestasis and fibrosis. The transcriptional process and plasma membrane localization of transporters are regulated by nuclear receptors and scaffold proteins, respectively. However, the detailed changes of these factors in the livers of BDL rats remain unclear. To clarify the effects of BDL on the levels of transporters and metabolizing enzymes, nuclear receptors, and scaffold proteins, we investigated changes in mRNA and protein levels of livers from BDL rats. METHODS: Membrane proteins and microsomes were prepared from rats with BDL. The mRNA levels of transporters and nuclear receptors in livers of control and BDL rats were examined by real-time reverse transcription polymerase chain reaction. The protein levels of transporters, metabolizing enzymes and scaffold proteins in membrane proteins and microsomes were determined by liquid chromatography-tandem mass spectrometry-based targeted proteomics. RESULTS: Mdr1a mRNA was significantly decreased at 1 and 2 weeks of BDL. The mRNA levels of MRP2 were significantly decreased. The mRNA levels of nuclear receptors were significantly decreased in livers of 1-week BDL rats. The protein levels of P-gp were significantly increased by BDL. Regarding scaffold proteins, the protein levels of ezrin, moesin and EBP50 were significantly decreased at 2 weeks of BDL. The protein levels of radixin were significantly increased at 1 week of BDL. In 1-week BDL rats, the protein levels of metabolizing enzymes such as CYP and UGT were significantly decreased. CONCLUSIONS: This study reports the comprehensive changes of transporters, metabolizing enzymes, nuclear receptors, and ezrin/radixin/moesin proteins in the livers of BDL rats. The expression levels of nuclear receptors and radixin that regulate the transcription and localization of CYP and/or transporters were decreased by BDL.
  • Radixin knockdown improves the accumulation and efficiency of methotrexate in tumor cells
    Atsushi Kawase; Yuta Inoue; Sayaka Nakazaki; Erika Koizumi; Masahiro Iwaki
    Oncol Rep 42 283 - 290 2019年 [査読有り]
  • Prediction of hepatic clearance of stereoselective metabolism of carvedilol in liver microsomes and hepatocytes of Sprague-Dawley and cytochrome P450 2D-dificient Dark Agouti rats
    Masahiro Iwaki; Toshiro Niwa; Hiroyuki Tanaka; Atsushi Kawase; Hiroshi Komura
    22 72 - 84 2019年 [査読有り]
  • Involvement of diclofenac acyl-b-d-glucuronide in diclofenac-induced cytotoxicity in glutathione-depleted isolated murine hepatocytes co-cultured with peritoneal macrophages
    Atsushi Kawase; Ayaka Kaneto; Mao Ishibashi; Akihiro Kobayashi; Hiroaki Shimada; Masahiro Iwaki
    29 3 203 - 210 2019年 [査読有り]
  • Takaya Uno; Kyoichi Wada; Sachi Matsuda; Yuka Terada; Nobue Terakawa; Akira Oita; Satoshi Yokoyama; Atsushi Kawase; Kouichi Hosomi; Mitsutaka Takada
    European journal of clinical pharmacology 75 1 67 - 75 2019年01月 [査読有り]
     
    PURPOSE: This study aimed to investigate the effects of clotrimazole on the pharmacokinetics of tacrolimus in Japanese patients with heart transplants with different CYP3A5 genotypes. METHODS: Twenty-six patients who underwent heart transplantation between June 2012 and July 2017 were enrolled in this retrospective study. The CYP3A5 (rs776746; CYP3A5*3) genotype was determined after monitoring and analysing tacrolimus blood concentrations. The pharmacokinetic profile of tacrolimus was examined before and after the discontinuation of clotrimazole and in patients with different CYP3A5 genotypes. RESULTS: The CYP3A5*1/*1, *1/*3 and *3/*3 genotypes were detected in 2, 8 and 16 patients, respectively. After clotrimazole was discontinued, the CYP3A5 expresser (CYP3A5*1/*1 or *1/*3) group had a 3.3-fold median increase in apparent oral clearance of tacrolimus (0.27 vs. 0.89 L/h/kg, P = 0.002) compared with the CYP3A5 non-expresser (CYP3A5*3/*3) group with a 2.2-fold median increase (0.18 vs. 0.39 L/h/kg, P < 0.0001). Significant correlations were observed between C0 and area under the concentration-time curve (AUC0-12) of tacrolimus after the discontinuation of clotrimazole in the CYP3A5 expresser and non-expresser groups, respectively (R2 = 0.49 and 0.42, all P < 0.05), but not before the discontinuation of clotrimazole. CONCLUSION: The effects of clotrimazole on tacrolimus pharmacokinetics in the CYP3A5 expresser patients were significantly greater than those in the CYP3A5 non-expresser patients. In addition, clotrimazole disturbed the correlation between C0 and AUC0-12 of tacrolimus. Careful dose adjustment of tacrolimus based on CYP3A5 genotypes may be beneficial for the patients with heart transplants who are concomitantly treated with clotrimazole.
  • Takaya Uno; Kyoichi Wada; Sachi Matsuda; Yuka Terada; Akira Oita; Atsushi Kawase; Mitsutaka Takada
    European Journal of Drug Metabolism and Pharmacokinetics 43 6 1 - 9 2018年04月 [査読有り]
     
    Background and Objective: Tacrolimus, a major immunosuppressant used after transplantation, is associated with large interindividual variation involving genetic polymorphisms in metabolic processes. A common variant of the cytochrome P450 (CYP) 3A5 gene, CYP3A5*3, affects blood concentrations of tacrolimus. However, tacrolimus pharmacokinetics at the early stage of transplantation have not been adequately studied in heart transplantation. We retrospectively examined the impact of the CYP3A5 genotype on tacrolimus pharmacokinetics at the early stage of heart transplantation. Methods: The tacrolimus pharmacokinetic profile was obtained from 65 patients during the first 5 weeks after heart transplantation. Differences in the patients’ characteristics and tacrolimus pharmacokinetic parameters between the CYP3A5 expresser (*1/*1 or *1/*3 genotypes) and non-expresser (*3/*3 genotype) groups were assessed by the Chi-square test, Student’s t test, or Mann–Whitney U test. Results: The CYP3A5 *1/*1, *1/*3, and *3/*3 genotypes were detected in 5, 22, and 38 patients, respectively. All patients started clotrimazole therapy approximately 1 week after starting tacrolimus. Apparent clearance and dose/weight to reach the target trough concentration (C0) were significantly higher in the expresser group than in the non-expresser group (0.32 vs. 0.19 L/h/kg, p = 0.0003 0.052 vs. 0.034 mg/kg/day, p = 0.0002) there were no significant differences in the area under the concentration-time curve from 0 to 12 h (AUC0–12) and concentrations at any sampling time point between the two groups. Conclusion: Similar concentration–time curves for tacrolimus were obtained in the expresser and non-expresser groups by dose adjustment based on therapeutic drug monitoring. These results demonstrate the importance of the CYP3A5 genotype in tacrolimus dose optimization based on therapeutic drug monitoring after heart transplantation.
  • 各世代のとろみ調整剤が血糖値に与える影響
    松浦正佳; 島田紘明; 岸本理咲; 藤本和佳; 大鳥徹; 川瀬篤史; 岩城正宏
    薬局薬学 10 1 131 - 139 2018年04月 [査読有り]
  • Hiroaki Shimada; Yuri Kobayashi; Sakiko Tanahashi; Atsushi Kawase; Taro Ogiso; Masahiro Iwaki
    European Journal of Pharmaceutical Sciences 112 132 - 138 2018年01月 [査読有り]
     
    Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause idiosyncratic liver injury. Mechanisms involved in NSAID-induced liver injury are complex. Previous studies have suggested that acyl glucuronide of NSAIDs (NSAIDs-Glu) plays an important role in the development of liver injury via covalently binds to proteins and the resultant adduct induces immunological toxicity. As only some NSAIDs-Glu are commercially available, the evaluation of covalent protein adduct formation using ready-made NSAIDs-Glu is difficult and inconvenient. Moreover, glucuronidation potency varies with the NSAID, including stereoisomers. Therefore, in this study, we simultaneously examined the glucuronidation and covalent adduct formation using enantiomers of parent NSAIDs (ibuprofen, naproxen, pranoprofen, ketoprofen, and flurbiprofen) in rat liver microsomes. Glucuronides and covalent adducts were quantified by HPLC. The amount of covalent adduct increased with NSAIDs-Glu formation in the rat liver microsomes in a time-dependent manner. A significant positive correlation was observed between the AUC of NSAIDs-Glu and that of covalent adduct, except ketoprofen. Although ketoprofen exhibited the highest glucuronidation rate among the NSAIDs investigated, the amount of covalent adduct was similar to that for pranoprofen, which had the lowest glucuronidation rate. Thus, it may be difficult for ketoprofen glucuronide to covalently bind with proteins in the rat liver microsomes. Our results suggested that the amount of glucuronide formed is a key factor in predicting covalent bond formation with protein in NSAIDs, in addition to degradability and bindability with proteins of NSAIDs-Glu. Further studies are required to confirm the relationship between the tendency of glucuronidation and the formation of covalent adducts of NSAIDs.
  • Impact of the CYP3A5 genotype on the pharmacokinetics of tacrolimus in Japanese heart transplant patients
    Takaya Uno; Kyoichi Wada; Sachi Matsuda; Yuka Terada; Akira Oita; Atsushi Kawase; Mitsutaka Takada
    Eur J Drug Metabol Pharmacokinet 2018年 [査読有り]
  • Masahiro Iwaki; Toshiro Niwa; Yukiko Nakamura; Atsushi Kawase; Hiroshi Komura
    Journal of Toxicological Sciences 43 1 59 - 63 2018年 [査読有り]
     
    The relative contribution of cytochrome P450 (CYP) isoforms responsible for carvedilol (CAR) oxidation in rats were evaluated in order to compare with that of reported human CYPs responsible for the metabolism of CAR enantiomers. The depletion of CAR enantiomers by recombinant CYPs and the effects of CYP-selective inhibitors on the depletion catalyzed by rat liver microsomes (RLM) was determined. Quinine (rat CYP2D inhibitor) markedly inhibited the metabolism of both R- and S-CAR by RLM. The metabolism of S-CAR was inhibited more than that of R-CAR by furafylline, (a CYP1A2 inhibitor, 53.5% vs 11.3%), α-naphthoflavone (a CYP1A2 inhibitor, 64.5% vs 33.6%), and ketoconazole (a CYP3A inhibitor, 87.1% vs 51.2%). Among the CYPs examined, CYP2D2 showed the highest metabolic activities against both the enantiomers. R-CAR was mainly metabolized by CYP2D2 and CYP3A2. CYP2C11 and CYP3A1, in addition to CYP2D2 and CYP3A2 showed higher metabolic activities against S-CAR than that against R-CAR. These results suggest that CYP2D2 predominantly catalyzed R-CAR metabolism, whereas CYP2D2 and CYP3A1/2 catalyzed S-CAR metabolism in rats.
  • 各世代のとろみ調整剤が血糖値に与える影響
    松浦正佳; 島田紘明; 岸本理咲; 藤本和佳; 大鳥徹; 川瀬篤史; 岩城正宏
    The Journal of Community Pharmacy and Pharmaceutical Sciences 10 1 - 9 2018年 [査読有り]
  • Profiling of hepatic metabolizing enzymes and nuclear receptors in rats with adjuvant arthritis by targeted proteomics
    Atsushi Kawase; Shunsuke Tateishi; Akira Kazaoka
    Biopharm Drug Dispos 39 6 308 - 314 2018年 [査読有り]
  • Shimada, Hiroaki; Urabe, Yuichi; Okamoto, Yuhei; Li, Zheng; Kawase, Atsushi; Morikawa, Toshio; Tu, Pengfei; Muraoka, Osamu; Iwaki, Masahiro
    JOURNAL OF FUNCTIONAL FOODS 39 91 - 95 2017年12月 [査読有り]
     
    Echinacoside (ECH) and acteoside (ACT), the major constituents of Cistanche tubulosa, suppress the increase in postprandial blood glucose level. Although ECH and ACT have been reported to weakly inhibit alpha-glucosidases, the underlying mechanism remains unclear. Therefore, we focused on the regulatory mechanism of dietary glucose absorption: In this study, we aimed to clarify the inhibitory effects of ECH and ACT on sodium-dependent glucose cotransporter (SGLT) 1-mediated gastrointestinal glucose absorption. Uptake experiments were performed using human intestinal Caco-2 cells and the fluorescence glucose analogue, 2-deoxy-2-[(7-nitro-2,1,3benzoxadiazol-4-yDaminc]-n-glucose (2-NBDG). Sodium-dependent 2-NBDG uptake was successfully estimated and this uptake was completely inhibited by an SGLT inhibitor phlorizin. ECH and ACT inhibited sodium-dependent 2-NBDG uptake in a concentration-dependent manner. However, this inhibition was not observed under sodium-free condition. This study suggested that the inhibitory effects of ECH and ACT on SGLT1-mediated glucose uptake contribute to suppression of increased postprandial blood glucose level.
  • Atsushi Kawase; Ayumi Handa; Masahiro Iwaki
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS 42 3 519 - 526 2017年06月 
    Background and Objectives Various nutrients modulate the expression of transporters; however, the effect of a high-cholesterol (HC) diet on the expression and function of hepatic transporters remains unclear. Here, we examined the effects of an HC diet on drug disposition via hepatic transporters, including organic anion-transporting polypeptide (Oatp), multidrug resistance-associated protein (Mrp), and bile salt export pump (Bsep). Methods In situ perfused rat liver system was performed. The levels of pravastatin, which is taken up into hepatocytes by Oatp and excreted into bile by Mrp2, in the perfusate and in bile were measured using high-performance liquid chromatography. Results Pravastatin was rapidly eliminated in control and HC rats; however, the cumulative amounts of excreted in bile were significantly higher in HC rats than in controls possibly because of the enhanced bile flow in HC rats (0.93 +/- 0.05 mu L/min in control, and 1.22 +/- 0.18 mu L/min in HC). Real-time reverse-transcriptase polymerase chain reaction (PCR) and western blot assessment of the mRNA and protein levels of hepatic transporters showed a significant downregulation of the Oatp1a1 and Bsep proteins in HC rats, whereas no differences in Mrp2 and Mrp3 levels were observed between HC and control rats. The analysis of the localization of Mrp2 on the canalicular membrane by immunofluorescence showed no changes in HC rats, although Mrp2 was readily internalized from the canalicular membrane under specific conditions. Conclusions The findings of the present study indicate that the HC diet affected the biliary excretion of pravastatin concomitant with increased bile flow, despite minimal effects on the expression of hepatic transporters. The HC diet could promote the biliary excretion of other drugs and metabolites that are substrates of Mrp2 and Bsep.
  • Atsushi Kawase; Ryota Hashimoto; Mai Shibata; Hiroaki Shimada; Masahiro Iwaki
    INTERNATIONAL JOURNAL OF TOXICOLOGY 36 3 260 - 267 2017年05月 
    Background and Objectives: Diclofenac (DIC) is metabolized to reactive metabolites such as diclofenac acyl--d-glucuronide (DIC-AG). It is possible that such reactive metabolites could cause tissue damage by formation of covalent protein adducts and other modification of cellular proteins or by induction of immune responses against its covalent protein adducts. However, the detailed mechanisms of idiosyncratic drug-induced liver injury (DILI) have been unclear. The objective is to clarify the involvement of DIC-AG and 4hydroxydiclofenac (4OH-DIC) in acute DILI.Methods:We examined the effects of inhibiting DIC-AG and 4OH-DIC production on covalent protein adduct formation and lactate dehydrogenase leakage using sandwich-cultured rat hepatocytes (SCRHs).Results:After pretreatment of SCRH with (-)-borneol (BOR, a uridine diphosphate (UDP)-glucuronosyltransferase inhibitor) or sulfaphenazole (SUL, a cytochrome P450 2C9 inhibitor) for 30 minutes, intracellular concentrations of DIC, DIC-AG, and 4OH-DIC were determined after further treating cells with 300 M DIC for 3 hours. The decreased levels of reactive metabolites caused by BOR or SUL pretreatment resulted in decreased lactate dehydrogenase leakage from SCRH, although the formation of covalent protein adducts was not affected.Conclusion:These results suggested that both DIC-AG and 4OH-DIC may be involved in acute cytotoxicity by DIC.
  • Misato Uraki; Atsushi Kawase; Hiroyuki Sayama; Yuka Matsushima; Masahiro Iwaki
    JOURNAL OF PHARMACEUTICAL SCIENCES 106 4 1175 - 1182 2017年04月 
    The reactive metabolites of diclofenac (DF) such as 1-O-acyl glucuronide (DF-Glu) are hypothesized to result in idiosyncratic hepatotoxicity. However, it is unclear whether inflammation affects the hepatic disposition of DF and its metabolites. To clarify the alterations in the disposition of DF and its metabolites in inflammatory conditions, we performed in situ perfused rat liver experiments. Using adjuvant arthritis rats as a model of inflammation, the elimination of DF, 4'-hydroxydiclofenac, and DF-Glu from the perfusate was observed to be delayed in comparison with the control. Parameter sensitivity analysis for hepatic DF disposition revealed that the area under the plasma concentration-time curve (AUC) and the maximum concentration (C-max) of DF-Glu in the liver markedly increased along with a decrease in intrinsic excretion clearance of DF-Glu (CLint,bile,Glu) and an increase in intrinsic glucuronidation clearance (CLint,Glu) of DF-Glu. It is possible that the elimination of DF-Glu from the perfusate in adjuvant arthritis rats was delayed via reduction of biliary excretion of DF-Glu. (C) 2017 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
  • Hiroyuki Ikuta; Atsushi Kawase; Masahiro Iwaki
    DRUG METABOLISM AND DISPOSITION 45 3 316 - 324 2017年03月 
    2-Arylpropionic acid (2-APA) nonsteroidal anti-inflammatory drugs are commonly used in racemic mixtures (rac) for clinical use. 2-APA undergoes unidirectional chiral inversion of the in vivo inactive R-enantiomer to the active S-enantiomer. Inflammation causes the reduction of metabolic activities of drug-metabolizing enzymes such as cytochrome P450 (P450) and UDP-glucuronosyltransferase. However, it is unclear whether inflammation affects the stereoselective pharmacokinetics and chiral inversion of 2-APA such as ibuprofen (IB). We examined the effects of inflammation on the pharmacokinetics of R-IB and S-IB after intravenous administration of rac-IB, R-IB, and S-IB to adjuvant-induced arthritic (AA) rats, an animalmodel of inflammation. The plasma protein binding of rac-IB, glucuronidation activities for R-IB and S-IB, and P450 contents of liver microsomes in AA rats were determined. Total clearance (CLtot) of IB significantly increased in AA rats, although the glucuronidation activities for IB, and P450 contents of liver microsomes decreased in AA rats. We presumed that the increased CLtot of IB in AA rats was caused by the elevated plasma unbound fraction of IB due to decreased plasma albumin levels in AA rats. Notably, CLtot ofR-IB but not S-IB significantly increased in AA rats after intravenous administration of rac-IB. These results suggested that AA could affect drug efficacies after stereoselective changes in the pharmacokinetics of R-IB and S-IB.
  • Stability evaluations of montelukast tablets under conditions of single dose packaging
    Masayoshi Matsuura; Toru Otori; Atsushi Kawase; Hiroaki Shimada; Hideyuki Nakanishi; Masahiro Iwaki
    Int J Pharm Tech 9 4 31079 - 31087 2017年 [査読有り]
  • Misato Uraki; Atsushi Kawase; Masahiro Iwaki
    XENOBIOTICA 47 11 943 - 950 2017年 
    1. The effects of adjuvant-induced arthritis (AA) on the stereoselective hepatic disposition and chiral inversion of "profens" have scarcely been investigated. Ibuprofen (IB) undergoes unidirectional chiral inversion from R-IB to S-IB and is metabolized to IB-glucuronide (IB-Glu). 2. We used an in situ perfused rat liver system to clarify the effects of inflammation on the metabolic activities and chiral inversion of IB without protein binding. 3. After dosing of R-IB, AA had minimal effect on the elimination of R-IB from the perfusate. Larger amounts of S-IB-Glu than R-IB-Glu were observed in the bile at the dose of 2.4 and 4.8 mol. However, after dosing of S-IB, the elimination of S-IB from the perfusate in AA rats was delayed, indicating a significant decrease in the hepatic clearance in AA rats. The cumulative biliary excretion of S-IB-Glu in AA rats was promoted after dosing with S-IB. There was little difference between the chiral inversion ratios of the control and AA rats. 4. The present study demonstrated that AA results in the delayed elimination of S-IB, the active form, without changes to the chiral inversion ratio. Thus, further attention to the altered stereoselective pharmacokinetics of IB during inflammation is required.
  • Toru Otori; Sumio Matzno; Atushi Kawase; Masahiro Iwaki; Tetsutaro Kimachi; Keiji Nishiwaki; William C. Figoni; Ryuta Tominaga; Mai Asahide; Mayumi Nishikata; Yoshikazu Ishii; Kenji Matsuyama
    JOURNAL OF PHARMACY AND PHARMACOLOGY 68 12 1527 - 1534 2016年12月 
    ObjectivesTo avoid the chelate formation between levofloxacin (LVFX) and aluminium hydroxide in gastrointestinal tract, an ethoxycarbonyl 1-ethyl hemiacetal ester of levofloxacin (LVFX-EHE) was synthesised as a prodrug. MethodsThe effects of aluminium hydroxide on the bioavailability of LVFX following oral administration of LVFX-EHE were investigated in rats. Furthermore, the effects of aluminium hydroxide on small intestinal absorption of LVFX and LVFX-EHE when subjected to a hydrolysis experiment using in situ everted gut sac were investigated, and the minimal inhibitory concentrations (MICs) of LVFX and LVFX-EHE for various intestinal bacteria were measured. Key findingsWhen LVFX-EHE was co-administered with and without aluminium hydroxide, the AUC(0-4 h) values of LVFX hydrolysed from LVFX-EHE were similar to that of LVFX alone. In everted gut sac experiments, LVFX-EHE was efficiently absorbed even in the presence of aluminium ions after 1 h of incubation, whereas the absorption of LVFX decreased significantly in the presence of aluminium ions. MIC values of LVFX-EHE were far higher than LVFX. ConclusionsThis study suggests the benefit of ethoxycarbonyl 1-ethyl hemiacetal esterification of the carboxyl group of new quinolone as a prodrug which is able to avoid chelate formation.
  • Masahiro Iwaki; Toshiro Niwa; Saya Bandoh; Megumi Itoh; Hitomi Hirose; Atsushi Kawase; Hiroshi Komura
    DRUG METABOLISM AND PHARMACOKINETICS 31 6 425 - 432 2016年12月 
    To evaluate the relative contribution of cytochrome P450 (CYP) isoforms responsible for carvedilol (CAR) oxidation, enantioselective metabolism of CAR was investigated in human liver microsomes (HLMs) and recombinant human CYPs by using the substrate depletion assay. CYP2D6 exhibited the highest contribution to the metabolism of R-CAR, followed by CYP3A4, CYP1A2, and CYP2C9, whereas the metabolism of the S-enantiomer was mainly mediated by CYP1A2, followed by CYP2D6 and CYP3A4. In HLMs, metabolism of R-and S-CAR was markedly inhibited by quinidine; R-CAR metabolism (57-61% decrease) was more inhibited than S-CAR metabolism (37-43% decrease), and furafylline and ketoconazole almost equally inhibited metabolism of both enantiomers by 25-32% and 30-50%, respectively. The absence of CYP2D6 in a mixture of five major recombinant CYP isoforms at the approximate ratio as in HLMs resulted in a 42% and 25% decrease in the metabolic activities for R-and S-CAR, respectively. Moreover, the absence of CYP1A2 in the mixture resulted in a 16% and 39% decrease in the metabolic activities for R-and S-CAR, respectively. Our results suggest the stereoselective metabolism of CAR is determined by not only the activity of CYP2D6 but also of CYP1A2 and CYP3A4. (C) 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
  • Atsushi Kawase; Hiroyuki Tanaka; Toru Otori; Kenji Matsuyama; Masahiro Iwaki
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES 11 5 662 - 667 2016年10月 
    Phenytoin (5,5-diphenylhydantoin; DPH) induces expression of cytochromes P450 (CYPs). Interactions between DPH and tacrolimus suggested that the persistence of CYP induction after discontinuation of DPH is dependent on the history of administration and dosing period of DPH. However, the relationship between the duration of DPH administration and expression of CYPs in the liver and small intestine of rats is not known. Alterations in levels of P-glycoprotein (P-gp; MDR1; ABCB1) as well as CYPs cause drug interactions in the small intestine. We examined the effects of the duration of DPH administration on expression of CYPs and P-gp in the liver and small intestine of rats. Rats were treated with DPH (100 mg/kg, peroral (p.o.) twice a day (b.d.)) for 2, 4, 8, and 16 d. mRNA levels of CYPs and P-gp were examined using the total RNA extracted from the liver and duodenum 2 h and 24 h after the final administration of DPH. CYP3A activities were determined using microsomes. DPH administration for 2 d and 4 d markedly increased mRNA levels of CYPs such as CYP3A1, CYP3A2, CYP2B1, and CYP2B2 in the liver. A relatively long duration of DPH administration (8 d and 16 d) resulted in abolition of the induction of hepatic CYP but increased CYP3A activities were maintained. These results suggest that the duration of DPH administration could be an important determinant of hepatic CYP induction. (C) 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V.
  • Atsushi Kawase; Yasuha Araki; Yukiko Ueda; Sayaka Nakazaki; Masahiro Iwaki
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS 41 4 457 - 463 2016年08月 
    Niemann-Pick C1-like 1 (NPC1L1), ATP-binding cassette (ABC)G5, and ABCG8 are all involved in intestinal cholesterol absorption. It is unclear whether a high-cholesterol (HC) diet affects the expression of these transporters in rats and mice as well as humans. We examined the effects of an HC diet on their expression in small intestine and the differences between rats and mice in the responsive of this expression to an HC diet. In addition to these transporters, alterations in six representative drug and nutrient transporters (multidrug resistance-associated protein, breast cancer resistance protein, peptide transporter, sodium-glucose linked transporter, glucose transporter, and l-type amino acid transporter) and transcriptional factors such as hepatocyte nuclear factor (HNF)4 alpha, sterol regulatory element-binding protein (SREBP)2, and liver X receptor (LXR)alpha were determined. In rats and mice fed an HC diet for 7 days, the mRNA and protein levels of NPC1L1 in the small intestine were determined by real-time reverse transcription polymerase chain reaction and western blotting, respectively. The mRNA levels of ABCG5 and ABCG8, six representative transporters, and transcriptional factors such as HNF4 alpha, SREBP2, and LXR were examined. Significant decreases in the expression levels of NPC1L1 were observed in mice, but not rats, fed the HC diet. The mRNA levels of ABCG5 and ABCG8 were significantly increased in HC rats but not in mice. Only minor changes in the mRNA levels of the other transporters were seen in HC rats and mice. Decreased mRNA levels of HNF4 alpha and SREBP2 in mice could be involved in the reduction in NPC1L1 expression observed upon the introduction of an HC diet. These results indicate that the effects of an HC diet on the expression levels of NPC1L1, ABCG5, and ABCG8 differ between mice and rats.
  • Misato Uraki; Atsushi Kawase; Yuka Matsushima; Masahiro Iwaki
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS 41 3 301 - 307 2016年06月 
    An in situ perfused rat liver system is useful for studying the hepatic disposition of drugs and their metabolites. However, the effects of the perfusion conditions on drug disposition are unclear. We examined the effects of conditions such as flow rate (13 or 26 mL/min) and bile acid on disposition of diclofenac (DF) as a model drug and DF metabolites [diclofenac-1-O-acyl glucuronide (DF-Glu) or 4'-hydroxydiclofenac (DF-4'OH)] in the absence of albumin. DF, DF-Glu, and DF-4'OH concentrations in the perfusate and cumulative amounts of DF-Glu excreted in bile were measured using high-performance liquid chromatography methods. DF in the perfusate was rapidly eliminated as the perfusate flow rate increased. The area under the plasma concentration-time curve from 0 to 60 min (AUC(0-60)) for DF-Glu and DF-4'OH in a perfusate containing bile acid was lower at a flow rate of 26 and 13 mL/min, respectively. The bile flow rate at 26 mL/min with 24 mu M of bile acid in the perfusate was significantly higher (ca. 3.5 times) compared with that at 13 mL/min without bile acid. Cumulative biliary DF-Glu excretion was also dramatically affected by the flow rate and addition of bile acid. This study indicated that the flow rate and bile acid in the perfused rat liver were key factors for bile flow rate and DF, DF-Glu, and DF-4'OH disposition in the absence of albumin.
  • Atsushi Kawase; Taiki Yamamoto; Sachiko Egashira; Masahiro Iwaki
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 356 2 366 - 374 2016年02月 
    Combined administration of methotrexate (MTX) and nonsteroidal anti-inflammatory drugs (NSAIDs) can result in a decreased systemic clearance of MTX. To date, inhibition of renal uptake via organic anion transporters and efflux via multidrug resistance-associated protein (MRPs) by NSAIDs has been recognized as possible sites of drug interaction between MTX and NSAIDs. Although most NSAIDs are glucuronidated in kidney tissue and excreted mainly as glucuronide conjugates, it is not fully known whether the glucuronides of NSAIDs (NSAIDs-Glu) inhibit MTX excretion via MRP2 and MRP4. The purpose of this study was to investigate the inhibitory effects of the glucuronides of several NSAIDs (diclofenac, R-and S-ibuprofen, R- and S-flurbiprofen, and R- and S-naproxen), as well as the parent NSAIDs on MTX uptake using human MRP2- and MRP4-expressing inside-out vesicles. Results confirm that all NSAIDs and NSAIDs-Glu examined exhibited stereoselective and concentration dependent inhibitory effects on MTX uptake via MRP2 and MRP4. Notably, NSAIDs-Glu potently inhibited MTX uptake via MRP2 and MRP4 compared with the corresponding parent NSAIDs except for naproxen in MRP2 and S-flurbiprofen in MRP4. The present results support that the glucuronides of NSAIDs, as well as the parent NSAIDs, are involved
  • Atsushi Kawase; Ayumi Handa; Masahiro Iwaki
    International Journal of Pharmacy and Pharmaceutical Sciences 8 12 130 - 134 2016年 
    Objective: Various nutrients such as glucose and cholesterol affect the expression of hepatic transporters. Although the pharmacokinetics of some drugs is affected by fasting, the fasting effects on drug hepatic disposition via alterations in transporters are unclear. Organic anion-transporting polypeptides and multidrug resistance-associated protein 2 (Mrp2/Abcc2) expressed in the liver are involved in hepatic disposition of pravastatin. Methods: An in situ perfused rat liver system was established. The mRNA and protein levels of transporters in the liver were examined by real-time reverse transcription PCR and western blotting. The localization of Mrp2 in hepatocytes was determined by immunostaining. Results: Pravastatin was rapidly eliminated from the perfusate. The cumulative biliary excretion amounts of pravastatin in fasting rats were significantly lower from 10 min compared with control. In fasting rats, the area under the plasma concentration-time curve (AUC)0‒∞ of pravastatin in the perfusate was significantly decreased, and hepatic clearance (CLh) and hepatic corrected clearance (CLcor) were significantly increased. The biliary clearance (CLbile) in fasting rats tended to decrease compared with that in control rats. Protein expression levels of transporters were unchanged after fasting. Confocal microscopy revealed a disruption of Mrp2 and ZO-1 colocalization in the liver of fasting rats. Conclusion: The biliary excretion of pravastatin was inhibited by fasting via decreased Mrp2 localization on the canalicular membrane.
  • Iwaki Masahiro; Kawase Atsushi; Sakata Misato; Nakasaka Misaki; Kato Yukio
    DRUG METABOLISM REVIEWS 47 275  2015年11月 [査読有り]
  • Atsushi Kawase; Ayami Ito; Ayano Yamada; Masahiro Iwaki
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS 40 2 239 - 244 2015年06月 
    Hepatic transporters and metabolic enzymes affect drug pharmacokinetics. Limited information exists on the alteration in mRNA levels of hepatic transporters and metabolic enzymes with aging. We examined the effects of aging on the mRNA levels of representative hepatic drug transporters and metabolic enzymes by analyzing their levels in 10-, 30- and 50-week-old male and female rats. Levels of mRNA of drug transporters including multidrug resistance protein (Mdr)1a, multidrug resistance-associated protein (Mrp)2, breast cancer resistance protein (Bcrp) and organic anion-transporting polypeptide (Oatp)1a1, and the metabolic enzymes cytochrome P450 (CYP)3A1, CYP3A2 and UDP-glucuronosyltransferase (UGT)1A1 were analyzed using real-time reverse transcriptase polymerase chain reaction. The mRNA levels of transporters in male rats did not decrease with age, while the mRNA levels of Bcrp and Oatp1a1 in female rats decreased with age. The mRNA levels of CYP3A1 and CYP3A2 in male rats were higher than those in female rats. The mRNA levels of metabolic enzymes decreased with age in female but not male rats. In particular, the mRNA levels of UGT1A1 in 10-week-old female rats were higher than those in male rats. mRNA expression of hepatic transporters and metabolic enzymes are more susceptible to aging in female than male rats. The age-related decreases in the mRNA levels of Bcrp, Oatp1a1, CYP3A1 and CYP3A2 in female rats may affect the metabolism and transport of substrates. This study showed that aging affected the mRNA expression of hepatic transporters and metabolic enzymes in rats.
  • Atsushi Kawase; Seiji Hata; Mai Takagi; Masahiro Iwaki
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES 18 5 765 - 772 2015年 
    Purpose. Niemann-Pick C1-like 1 (NPC1L1), ATP-binding cassette (ABC)G5, and ABCG8 mediate intestinal cholesterol absorption. It is unclear whether pravastatin (PR) or ezetimibe (EZ) affect expression of these transporters. We examined the effects of PR and EZ on NPC1L1, ABCG5, and ABCG8 expression in human hepatoma HepG2 cells and the murine small intestine. We also assessed expression of the transcription factors liver X receptor (LXR)alpha, LXR beta and sterol regulatory element-binding protein. Methods. Transporter mRNA levels were determined in murine small intestines 6 and 24 h after oral PR and EZ administration by real-time reverse-transcriptase polymerase chain reaction (RT-PCR). In PR-and EZ-treated HepG2 cells, transporter and transcription factor mRNA and protein levels were examined by RT-PCR and western blot, respectively. Results. Significant decreases in NPC1L1, ABCG5, and ABCG8 mRNA expression were observed in the duodenum, but not jejunum and ileum, of mice 24 h after treatment with PR, but not EZ. In HepG2 cells, PR but not EZ treatment for 24 h also significantly decreased NPC1L1 protein and ABCG5, and ABCG8 mRNA expression, while increasing LXR alpha mRNA levels. Conclusion. PR but not EZ treatment reduced duodenal cholesterol transporter expression in mice. PR-induced increases in LXR alpha mRNA levels may be involved in attenuation of NPC1L1 expression, subsequently decreasing intestinal cholesterol absorption.
  • Atsushi Kawase; Misato Sakata; Nagisa Yada; Misaki Nakasaka; Takuya Shimizu; Yukio Kato; Masahiro Iwaki
    JOURNAL OF PHARMACEUTICAL SCIENCES 103 12 4058 - 4065 2014年12月 
    Pathophysiological changes are associated with alterations in the expression and function of numerous ADME-related proteins. We have previously demonstrated that the membrane localization of ATP-binding cassette (ABC) transporters in liver was decreased without change of total expression levels in adjuvant-induced arthritis (AA) in rats. Ezrin/radixin/moesin (ERM) proteins are involved in localization of some ABC transporters in canalicular membrane. The mRNA levels of radixin decreased significantly in liver but not kidney, small intestine, and brain. The mRNA levels of ezrin and moesin did not change in AA. The membrane localization of radixin was reduced in liver of AA and the ratios of activated radixin (p-radixin) to total radixin were decreased in AA, although the protein levels of radixin did not change in homogenate and membrane protein. To clarify whether AA affects the linker functions of ERM proteins, we examined the interactions between ERM proteins and ABC transporters. The interactions between radixin and ABC transporters were decreased in AA. In vitro studies using human hepatoma HepG2 cells showed that interleukin-1 decreased the mRNA levels of radixin and colocalization of radixin and Mrp2. Our results show that the decreased radixin functions affect the interaction between radixin and ABC transporters in inflammation. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:4058-4065, 2014
  • Atsushi Kawase
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 134 9 925 - 929 2014年09月 
    Pathophysiological changes in infection or inflammation are associated with alterations in the production of numerous absorption-, distribution-, metabolism-, and excretion-related proteins. However, little information is available on the effects of inflammation on the expression levels and activities of ATP-binding cassette (ABC) transporters. We examined the effects of acute (on day 7) and chronic (on day 21) inflammation on the expression of ABC transporters in some major tissues in rats. Adjuvant-induced arthritis (AA) in rats was used as an animal model of inflammation. The mRNA levels of mdr1a and mdr1b encoding P-glycoprotein (P-gp) decreased significantly in the liver of AA rats on day 21. Hepatic protein levels of P-gp, Mrp2, and Bcrp decreased significantly in the membrane but not in the homogenate of AA rats after 7 days and after 21 days of treatment with adjuvant. Recently, ezrin/radixin/moesin (ERM) proteins have been found to show linker activity for some transporters and F-actin. We examined the expression levels and functions of ERM proteins in AA because the membrane localization of ABC transporters was decreased without any change in total expression levels. In this review, we summarize our recent work and reports of ERM proteins relevant to ABC transporters.
  • Atsushi Kawase; Sari Norikane; Ayaka Okada; Mamiko Adachi; Yukio Kato; Masahiro Iwaki
    JOURNAL OF PHARMACEUTICAL SCIENCES 103 8 2556 - 2564 2014年08月 
    Pathophysiological changes of infection or inflammation are associated with alterations in the production of numerous absorption, distribution, metabolism and excretion-related proteins. However, little information is available on the effects of inflammation on the expression levels and activities of ATP-binding cassette (ABC) transporters. We examined the effect of acute (on day 7) and chronic (on day 21) inflammation on the expression of ABC transporters in some major tissues in rat. Adjuvant-induced arthritis (AA) in rats was used as an animal model for inflammation. The mRNA levels of mdr1a and mdr1b encoding P-glycoprotein (P-gp) decreased significantly in livers of AA rats on day 21. Hepatic protein levels of P-gp, Mrp2, and Bcrp decreased significantly in membranes but not homogenates of AA rats after 7 days and after 21 days of treatment with adjuvant. Contrary to liver, protein levels of P-gp and Mrp2, but not Bcrp in kidney, increased significantly in membranes. The biliary excretion of rhodamine 123 was decreased in rats with chronic inflammation owing to decreases in efflux activities of P-gp. Our results showed that the expression of transporters in response to inflammation was organ dependent. In particular, hepatic and renal P-gp and Mrp2 exhibited opposite changes in membrane protein levels. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:2556-2564, 2014
  • Atsushi Kawase; Ayano Yamada; Yuko Gamou; Chika Tahara; Fumiaki Takeshita; Kazuya Murata; Hideaki Matsuda; Keiichi Samukawa; Masahiro Iwaki
    JOURNAL OF NATURAL MEDICINES 68 2 395 - 401 2014年04月 
    An extract from red ginseng (steamed and dried roots of Panax ginseng C.A. Meyer; RGE) has been shown to promote cholesterol metabolism in the liver. We have reported that RGE induced the hepatic expression of cytochrome P450 (CYP)7A1, involved in cholesterol metabolism. Other cholesterol metabolism-related proteins, such as CYP8B1, CYP27A1, multidrug resistance-associated protein (MRP)2, MRP3, and Na+ taurocholate cotransporting polypeptide (NTCP), are involved in cholesterol metabolism. The purpose of this study was to clarify whether RGE affected mRNA expression of cholesterol metabolism-related CYPs and transporters in the liver of hypercholesterolemic rats and rat primary hepatocytes. In-vivo studies showed little differences in CYP8B1, CYP27A1, MRP2, MRP3, and NTCP mRNA expression levels between hypercholesterolemic rats with or without RGE treatments. However, the disruption of the membrane localization of MRP2 was suppressed by RGE treatments in hypercholesterolemic rats. In-vitro studies using rat primary hepatocytes showed upregulation of CYP8B1 and MRP2 mRNA by the addition of RGE (100 and 500 mu g/mL). We further examined which ginsenosides contributed to the upregulation of CYP8B1 and MRP2 mRNA levels. Ginsenoside Re enhanced the mRNA level of CYP8B1, whereas ginsenosides Rb-2 and Rg(2) enhanced MRP2 mRNA levels. These results suggest that the in-vitro exposure of hepatocytes to RGE or some ginsenosides could lead to upregulation of CYP8B1 and MRP2, resulting in the alteration of biosynthesis and disposition of bile acids.
  • Keiji Nishiwaki; Atsushi Kawase; Tetsuyuki Wada; Hideki Yagi; Naohito Kawasaki; Eiji Ito; Masahiro Iwaki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 134 2 171 - 177 2014年02月 
    We conducted team-based learning (TBL) with interdisciplinary lectures as a part of "Introduction to Pharmacy", divided among the pharmacy department's six pharmacist education curricula in the first semester. The interdisciplinary lecture is led by seven lecturers, each specializing in one area: cell biology, biochemistry, chemistry, public health pharmacology, pharmacokinetics, and clinical science. This lecture's purpose is to demonstrate to the students that all field subjects relate to each other and they must learn the basic science subjects to understand pharmaceutical sciences. The TBL contents have two themes, "cancer" and "aspirin", each of which had two lectures, each 90 minutes long and were conducted using TBL as expansive learning. On receiving knowledge of a wide range of fields in one lecture, a small number of students indicated that they were unable to understand the contents very well. However, in the questionnaire about TBL, many students reported "I have understood" and "I have enjoyed studying" using TBL, especially group readiness assessment test (GRAT). By incorporating TBL, they reported "increasing eagerness to learn pharmacy". Overall, students seem to have accepted TBL favorably, but they still find peer review difficult. We believe that their discomfort with peer review results from their unfamiliarity in evaluating others, and the time before the evaluation is short because TBL is conducted only twice.
  • Atsushi Kawase; Ayano Yamada; Yuko Gamou; Chika Tahara; Fumiaki Takeshita; Kazuya Murata; Hideaki Matsuda; Keiichi Samukawa; Masahiro Iwaki
    Journal of Natural Medicines 67 3 545 - 553 2013年07月 
    An extract from red ginseng [steamed and dried roots of Panax ginseng C.A. Meyer (RGE)] has been shown to have various actions on physiological functions. The mechanisms by which RGE promotes cholesterol metabolism in the liver are unclear, but RGE decreases the plasma levels of cholesterol. We investigated whether RGE affected the mRNA expression of cholesterol metabolism-related proteins such as cytochrome P450 (CYP)7A1 and bile salt export pump (BSEP) in the liver in hypercholesterolemic rats and rat primary hepatocytes. In-vivo studies showed the upregulation of CYP7A1 mRNA in hypercholesterolemic rats treated with RGE. Treatment with RGE exhibited decreased ratios of low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol compared with hypercholesterolemia without RGE. In-vitro studies also showed the upregulation of CYP7A1 mRNA and protein levels by the addition of RGE to rat primary hepatocytes. The mRNA levels of BSEP exhibited few changes. The sustained levels of the liver X receptor (LXR) in vivo and the increased levels of LXR in vitro on RGE treatment could be involved in the upregulation of CYP7A1. To clarify the effects of 11 ginsenosides including RGE on the mRNA levels of CYP7A1 and BSEP, we performed in-vitro experiments using rat primary hepatocytes. The ginsenosides Ro, Rg3, Re, Rg1, and Rg2 exhibited increased mRNA levels of CYP7A1. These results suggest that several ginsenosides including RGE promoted cholesterol metabolism due to upregulation of CYP7A1. © 2012 The Japanese Society of Pharmacognosy and Springer Japan.
  • Atsushi Kawase; Hiroyuki Ikuta; Satoshi Uno; Kana Yamamoto; Naomi Akitsu; Tomoaki Nagao; Masahiro Iwaki
    XENOBIOTICA 43 3 246 - 252 2013年03月 
    Adjuvant-induced arthritis (AA) in the rat is used as a model for rheumatoid arthritis. In AA rats, the pharmacokinetics of various drugs is affected due to the alterations of plasma protein binding of drugs. We choose propranolol (PL) and flurbiprofen (FP) as model basic and acidic drugs, respectively, and investigated the effect of AA induction on their plasma protein binding at each developing stage of inflammation. The plasma protein binding of PL and FP was dramatically changed due to reduced albumin and increased alpha(1)-acid glycoprotein levels for at least 21 days after adjuvant treatment. Moreover, we illustrated the differences in protein binding in AA between both the drugs in each developing stage of inflammation. These results suggest that the changed plasma protein levels in AA rats accompanying the altered protein binding of drugs affect the pharmacokinetics of drugs which extensively bind to plasma protein under inflammatory condition.
  • Changes in mRNA Expression and Activity of Xenobiotic Metabolizing Enzymes in Livers from Adjuvant-induced Arthritis Rats
    Atsushi Kawase; Syoko Wada; Masahiro Iwaki
    Pharmacology & Pharmacy 4 478 - 483 2013年
  • Diurnal Variation of Nuclear Receptors in Mice with or without Fasting
    Atsushi Kawase; Tetsuya Ohgami; Iho Yoshida; Yu Tsunokuni; Masahiro Iwaki
    Pharmacology & Pharmacy 4 240 - 243 2013年
  • Atsushi Kawase; Toru Otori; Akiyuki Fujii; Ayano Yamada; Hiroshi Komura; Masahiro Iwaki
    JOURNAL OF HEALTH SCIENCE 57 5 414 - 419 2011年10月 
    Strain differences in the induction of cytochrome P450 (CYP) affect drug actions and side effects. Strain differences in the induction of CYP are important to evaluate drug-drug interactions in CYPs. We clarified strain differences in the induction of CYP3A1/3A2 and nuclear receptors by evaluating mRNA levels and metabolic activities in Sprague-Dawley (SD) rats and Dark Agouti (DA) rats (models for extensive and poor metabolism of CYP2D6, respectively). To clarify strain differences in CYP levels, we examined nuclear receptors such as the constitutive androstane receptor (CAR) and pregnane X receptor, which regulate the transcription of CYPs and transporters. We investigated CYP3A inductions in the liver after repeated intraperitoneal injections of phenobarbital (PB) or dexamethasone (DEX) into SD rats and DA rats for 3d. mRNA levels of CYP and nuclear receptors were determined by real-time reverse transcriptase-polymerase chain reaction. Metabolic activities of CYP3A were also determined. Increased CYP3A mRNA levels were observed in both rat strains after treatment with PB or DEX compared with the respective rat strains treated with vehicle alone. Induction of CYP3A mRNAs by DEX was higher in SD rats than in DA rats, suggesting that SD rats could be more susceptible to DEX than DA rats. Inductions of CAR by PB differed between strains. The increase in mRNA levels and activity of CYP3A by PB in SD rats and DA rats were similar. However, there were strain differences in CYP3A1/3A2 inductions after DEX treatment.
  • Kumiko Sugio; Fuminori Sakurai; Kazufumi Katayama; Katsuhisa Tashiro; Hayato Matsui; Kenji Kawabata; Atsushi Kawase; Masahiro Iwaki; Takao Hayakawa; Toshiyoshi Fujiwara; Hiroyuki Mizuguchi
    CLINICAL CANCER RESEARCH 17 9 2807 - 2818 2011年05月 
    Purpose: Oncolytic adenoviruses (Ad) have been actively pursued as potential agents for cancer treatment. Among the various types of oncolytic Ads, the telomerase-specific replication-competent Ad (TRAD), which possesses an E1 gene expression cassette driven by the human telomerase reverse transcriptase promoter, has shown promising results in human clinical trials; however, the E1 gene is also slightly expressed in normal cells, leading to replication of TRAD and cellular toxicity in normal cells. Experimental Design: To overcome this problem, we utilized a microRNA (miRNA)-regulated gene expression system. Four copies of complementary sequences for miR-143, -145, -199a, or let-7a, which have been reported to be exclusively downregulated in tumor cells, were incorporated into the 3'-untranslated region of the E1 gene expression cassette. Results: Among the TRAD variants (herein called TRADs) constructed, TRADs containing the sequences complementary to miR-143, -145, or -199a showed efficient oncolytic activity comparable to the parental TRAD in the tumor cells. On the other hand, replication of the TRADs containing the miRNA complementary sequences was at most 1,000-fold suppressed in the normal cells, including primary normal cells. In addition, to suppress the replication of the TRADs in hepatocytes as well as other normal cells, we constructed a TRAD containing 2 distinct complementary sequences for miR-199a and liver-specific miR-122a (TRAD-122a/199aT). TRAD-122a/199aT exhibited more than 10-fold reduction in viral replication in all the normal cells examined, including primary hepatocytes. Conclusions: This study showed that oncolytic Ads containing the sequences complementary to normal cell-specific miRNAs showed significantly improved safety profiles without altering tumor cell lysis activity. Clin Cancer Res; 17(9); 2807-18. (C)2011 AACR.
  • Tomohisa Yasuhara; Naohito Kawasaki; Hideki Yagi; Eiji Itoh; Atsushi Kawase; Toru Otori; Tetsuyuki Wada; Kenji Matsuyama; Masahiro Iwaki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 130 12 1647 - 1653 2010年12月 
    The six-year pharmacist education course has begun, and now first-year students receive clinical training. Interdisciplinary problem-solving capabilities covering chemistry, biology, molecular biology, pharmacology, pathology, and pharmacokinetics are necessary for new pharmacists. However, the conventional pharmaceutical science education was so separate from other fields that education for interdisciplinary cooperative capability was insufficient. This was especially true of elemental science courses, because they are not directly connected with clinical knowledge, and there is a problem of low student interest in those courses. As a result, students acquired only recall-level knowledge in clinical courses and their problem-solving capabilities in clinical treatment and drug development deteriorated. Therefore we offered a trial lecture aimed to help students recognize the important relationship between elemental science courses and clinical courses and increase their motivation to enroll in these courses. Specifically, the trial lecture covered cancer therapy, in reference to mechanisms of carcinogenesis, epidemiology, physiology of cancer, anticancer drugs with explanations of the mechanism of action of carcinogens, anticancer drugs, and molecular-targeted drugs from the viewpoints of organic chemistry and biochemistry by a specialized teacher. This paper reports on this experimental lecture with evaluations from students.
  • Hiroaki Fujimori; Masayoshi Hisama; Hiroharu Shibayama; Atsushi Kawase; Masahiro Iwaki
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY 74 5 918 - 922 2010年05月 
    To determine the component-activity relationships of phytoncide solutions on inhibitory activity in melanin biosynthesis, four types of phytoncide solution (A-type, AB-type, D-type, and G-type) were evaluated for inhibition of mushroom tyrosinase activity and melanin synthesis on murine B-16 melanoma cells and a human reconstituted skin model. The A-type, AB-type, D-type, and G-type of phytoncide solution treatment resulted in significant inhibition of tyrosinase activity. The amount of melanin was increased by treatment with phytoncide solutions in a concentration-dependent manner on murine B-16 melanoma cells without affecting cell growth. Furthermore, phytoncide solutions also suppressed melanin synthesis in a concentration-dependent manner on a human reconstituted skin model. These effects of A-type solution were superior to those of other solutions.
  • Atsushi Kawase; Fumiaki Takeshita; Ayano Yamada; Kazuya Murata; Hideaki Matsuda; Keiichi Samukawa; Masahiro Iwaki
    JOURNAL OF HEALTH SCIENCE 55 5 809 - 813 2009年10月 
    A 70% methanol extract from red ginseng (steamed and dried roots of Panax ginseng C. A. Meyer, a kind of Ginseng Radix) has been shown to have various actions on physiological functions. We investigated whether the ginseng extract (Ext.) affected the mRNA expression of cytochrome P450 (CYP) CYP1A1, 2B1, 2C11, 2D1, 3A1, and 3A2 in rat primary hepatocytes. After treatment with ginseng extract, the levels of CYP3A1 and 1A1 mRNA were significantly increased compared with those of the control. The increased protein levels of CYP3A1 were also observed after treatment with Ext. The mRNA levels of other examined CYPs exhibited little change. The mRNA levels of the pregnane X receptor, but not the constitutive androstane receptor, both transcription factors for CYPs, also significantly increased after treatment with ginseng extract. These results raise the possibility that ginseng Ext. promotes xenobiotic metabolism via an increase in CYP3A1. and 1A1 expression.
  • Keiko Isaji; Atsushi Kawase; Mitsuhiro Matono; Xin Guan; Makiya Nishikawa; Yoshinobu Takakura
    JOURNAL OF CONTROLLED RELEASE 135 3 227 - 233 2009年05月 
    To elicit a cytotoxic T lymphocytes (CTL) response efficiently after DNA vaccination, we constructed several plasmid DNA (pDNA) vectors encoding the major histocompatibility complex (MHC) class I-restricted epitope peptide (SIINFEKL) of ovalbumin (OVA) or OVA protein with modified intracellular trafficking. An in vitro antigen presentation assay was carried out using DC2.4 cells, a dendritic cell line, to examine the potentials of the constructs following direct transfection. Among the vectors, pPep-ER, pDNA encoding antigen peptide combined with an endoplasmic reticulum (ER)-retention signal, exhibited a significant ability of antigen presentation compared with the counterpart without the signal. Based on the in vitro results, we carried out in vivo immunization experiments using pPep-ER via the intradermal or intramuscular route in combination with electroporation in mice. pPep-ER showed an efficient antigen-specific CTL induction and the effect was superior to that exhibited by the positive control, OVA in complete Freund's adjuvant (CFA). The levels of interferon gamma (IFN-gamma) released from spleen cells were significantly increased by pPep-ER compared with pPep-free. Immunization with pPep-ER also exhibited a high inhibitory effect on the growth of E.G7 tumor. These results indicate that DNA vaccination with the pDNA vector expressing a MHC class I epitope peptide with controlled intracellular trafficking is a promising method of inducing an antigen-specific CTL response via direct presentation. (c) 2009 Elsevier B.V. All rights reserved.
  • Atsushi Kawase; Yukako Matsumoto; Motoshi Hadano; Yui Ishii; Masahiro Iwaki
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES 12 2 150 - 163 2009年 
    Purpose. The activities of breast cancer resistance protein (Bcrp/ABCG2) as well as P-glycoprotein (P-gp) and drug-metabolizing enzymes can be inhibited by several flavonoids or drugs in rats. However, the species, sex and regional differences of effects of flavonoids on Bcrp/ABCG2 in rats and mice remain unclear, although Bcrp, like P-gp, is also important in controlling drug absorption and disposition. Methods. We used chrysin as a model flavonoid because it possesses anti-inflammatory and antioxidative properties and is used as a dietary supplement. We examined the pharmacokinetics of nitrofurantoin, a specific Bcrp substrate, after oral or intravenous administration in rats and mice treated with chrysin. Bcrp mRNA levels were measured in liver, kidney, duodenum, jejunum and ileum in rats and mice. Results. Oral chrysin increased plasma concentrations of nitrofurantoin in rats but not mice. Intraperitoneal injection of chrysin into rats or mice had little effect on the elimination of nitrofurantoin. The AUC(0-t) in female mice was 1.5-2.0 folds higher than in male mice after oral and intravenous administration of nitrofurantoin. Absorption of nitrofurantoin from apical to basal sides was significantly increased by chrysin in both duodenum and jejunum as well as in ileum in rat small intestine. Conclusions. Chrysin-nitrofurantoin interactions it takes place in the small intestine and occur in rats, but not in mice, possibly due to the higher levels of Bcrp in the small intestine in rats as compared with mice.
  • Satoshi Uno; Misato Uraki; Ayami Ito; Yuki Shinozaki; Ayano Yamada; Atsushi Kawase; Masahiro Iwaki
    BIOPHARMACEUTICS & DRUG DISPOSITION 30 1 49 - 54 2009年01月 
    In this study, a real-time reverse transcription-polymerase chain reaction was used to determine the effects of adjuvant-induced arthritis (AA) on the amounts of mRNA of 12 types of rat ATP-binding cassette (ABC) and solute carrier (SLC) transporters in the liver and small intestine, 7 (D7) and 21 days (D21) after the injection of adjuvant. There were no significant differences in mRNA levels of ABC and SLC transporters between the livers of AA and control rats on D7, except in the case of Mdr1a. However, levels of Mdr1a, Mrp2 and Cap SLC transporters were significantly lower in AA than in the control livers on D21. In contrast, the mRNA levels of several ABC and SLC transporters, especially Mrp2, Bcrp, LAT2 and Oatp1a5, were significantly lower in the small intestines of AA rats compared with the controls on D7, though there were no significant differences by D21. The time-dependent alterations in mRNA levels of the pregnane X receptor, but not the constitutive androstane receptor, in the liver and intestine were similar to the changes in mRNA levels of most transporters examined. The present study showed that AA was associated with reduced mRNA expression of several ABC and SLC transporters in the liver and small intestine, but that the time courses of the effects of AA on mRNA expression differed between the liver and small intestine. These results raise the possibility of a functional change of the transporters of liver and intestine in AA rats. Copyright (C) 2009 John Wiley & Sons, Ltd.
  • Tadashi Fujita; Atsushi Kawase; Toshiro Niwa; Norimichi Tomohiro; Megumi Masuda; Hideaki Matsuda; Masahiro Iwaki
    BIOLOGICAL & PHARMACEUTICAL BULLETIN 31 5 925 - 930 2008年05月 
    In a previous study we found that 50% ethanol extracts of immature fruits of Citrus unshiu (satsuma mandarin) have anti-allergic effects against the Type I, II and IV allergic reactions. However, many adverse interactions between citrus fruit, especially grapefruit juice, and drugs have been reported due to the inhibition of cytochrome P450 (CYP) activities. The purpose of this study was to examine the competitive inhibitory effects of extracts from immature citrus fruit on CYP activity. Extracts were prepared from 12 citrus species or cultivars, and were tested against three kinds of major CYPs, CYP2C9, CYP2D6 and CYP3A4, in human liver microsomes. We also estimated the amounts of flavonoids (narirutin, hesperidin, naringin and neohesperidin) and furanocoumarins (bergapten, 6',7'-dihydroxybergamottin and bergamottin) in each extract using HPLC. Citrus paradisi (grapefruit) showed the greatest inhibition of CYP activities, while Citrus unshiu which has an antiallergic effect, showed relatively weak inhibitory effects. Extracts having relatively strong inhibitory effects for CYP3A4 tended to contain higher amounts of naringin, bergamottin and 6',7'-dihvdroxybergamottin. These results, providing comparative information on the inhibitory effects of citrus extracts on CYP isoforms, suggest that citrus extracts containing high levels of narirutin and hesperidin and lower levels of furanocoumarins such as C. unshiu are favorable as antiallergic functional ingredients.
  • Hiroharu Shibayama; Masayoshi Hisama; Sanae Matsuda; Atsushi Kawase; Mamitaro Ohtsuki; Katsumi Hanada; Masahiro Twaki
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY 72 4 1015 - 1022 2008年04月 
    The novel amphiphilic vitamin C derivative disodium isostearyl 2-O-L-ascorbyl phosphate (VCP-IS-2Na), which has a C-18 alkyl chain attached to the stable ascorbate derivative sodium L-ascorbic acid 2-phosphate (VCP-Na), was evaluated for reduction of cell damage induced by oxidative stress, ultraviolet A (UVA), ultraviolet B (UVB), and H2O2; stimulation of collagen synthesis against UVA irradiation; and inhibition of matrix metalloproteinase-1 (MMP-1) activity induced by UVA in human normal dermal fibroblasts. VCP-IS-2Na pretreatment resulted in significant protection against cell damage induced by UVB, UVA, and H2O2. The amount of type I collagen following UVA irradiation was increased by treatment with VCP-IS-2Na in a concentration-dependent manner. These effects of VCP-IS-2Na were superior to those Of L-ascorbic acid (vitamin C, VC) and VCP-Na. On the other hand, VCP-IS-2Na suppressed 65% of the excess MMP-1 irradiated UVA, and VC and VCP-Na slightly suppressed it.
  • Tadashi Fujita; Takehumi Shiura; Megumi Masuda; Masashi Tokunaga; Atsushi Kawase; Masahiro Iwaki; Takeshi Gato; Masahiko Fumuro; Katsuaki Sasaki; Naoki Utsunomiya; Hideaki Matsuda
    JOURNAL OF NATURAL MEDICINES 62 2 202 - 206 2008年04月 
    Effect of 50% ethanolic extract of unripe fruits of Citrus unshiu (CU-ext) on type IV allergic reaction was examined by inhibitory activity of ear swelling of picryl chloride-induced contact dermatitis (PC-CD) in mice. Oral administration of CU-ext and subcutaneous administration of prednisolone showed inhibition of ear swelling during both induction and effector phases of PC-CD. The inhibitory activities of combinations of CU-ext (p.o.) and prednisolone (s.c.) during induction phase of PC-CD were more potent than those of CU-ext alone and prednisolone alone. Successive oral administration of hesperidin, a major flavanone glycoside of CU-ext, inhibited ear swelling during induction phase of PC-CD. The inhibitory activities of combinations of hesperidin (p.o.) and prednisolone (s.c.) were more potent than those of hesperidin alone and prednisolone alone. These results indicated that the combinations of prednisolone and CU-ext or hesperidin exerted a synergistic effect.
  • Iwaki Masahiro; Uno Satoshi; Kawase Atsushi
    DRUG METABOLISM REVIEWS 40 213 - 214 2008年 [査読有り]
  • S. Uno; M. Uraki; H. Komura; H. Ikuta; A. Kawase; M. Iwaki
    XENOBIOTICA 38 11 1410 - 1421 2008年 
    1. The effects of adjuvant-induced arthritis on the chiral inversion of 'profens', a type of non-steroidal anti-inflammatory drug, have hardly been investigated. The authors investigated the effects of adjuvant-induced arthritis on the chiral inversion of ibuprofen using freshly isolated rat hepatocytes. 2. S- or R-ibuprofen was incubated with hepatocytes isolated from control and adjuvant-induced arthritis rats in the absence of the serum. In the hepatocyte system the chiral inversion rate constant of R- to S-ibuprofen and the metabolic rate constants of both enantiomers in adjuvant-induced arthritis rats were significantly decreased to about 64-80% of the corresponding values in control rats. In contrast, the addition of serum from each group to the corresponding hepatocyte medium resulted in no significant differences in these rate constants between control and adjuvant-induced arthritis rats. 3. With regard to chiral inversion enzymes, adjuvant-induced arthritis decreased the messenger RNA levels of acyl-coenzyme A synthetase (ACS) isoforms, but not 2-arylpropionyl-CoA epimerase, compared with control rats. 4. Chiral inversion of R- to S-ibuprofen was inhibited by triacsin C, a specific inhibitor of ACS1. 5. The results suggest that adjuvant-induced arthritis induces down-regulation of ACS enzymes involved in chiral inversion of R- to S-ibuprofen in rats.
  • S. Uno; A. Fujii; H. Komura; A. Kawase; M. Iwaki
    XENOBIOTICA 38 5 482 - 495 2008年 
    1.The purpose of this study was to evaluate drug clearance measured by the metabolic intrinsic clearance (CLint) in a substrate depletion assay in comparison with the in vivo clearance (CLtot) observed in adjuvant-induced arthritis (AA) rats. 2. After intravenous administration of diclofenac as a model drug, CLtot was 2.8-fold higher in AA rats than in control rats. In two different substrate depletion assays with liver microsomes for glucuronidation and hydroxylation, the CLint values for glucuronidation was significantly decreased in AA rats to 60% of the value in control rats, whereas the CLint values for hydroxylation were similar. The unbound fraction of diclofenac in plasma (fu, plasma) was significantly higher (2.8-fold) in AA rats than in control rats. 3. Hepatic clearance predicted from the CLint values for both biotransformation pathways and fu, plasma was higher in AA rats than in control rats, with good consistency between predicted and observed values. The same results were obtained for experiments using hepatocytes. 4. The plasma protein-binding activities, rather than metabolic clearance, in both types of rats would be a determining factor in the pharmacokinetic behaviour differences between control and AA rats. 5. In summary, substrate depletion assays with liver microsomes and hepatocytes in combination with protein binding assessment can help to predict changes in pharmacokinetics under AA conditions.
  • Tadashi Fujita; Atsushi Kawase; Nanae Nishijima; Megumi Masuda; Hideaki Matsuda; Masahiro Iwaki
    Shoyakugaku zasshi 62 1 8 - 14 日本生薬学会 2008年 
    Hesperidin and hesperetin having an antiallergic effect are contained abundantly in immature fruit of Citrus unshiu. However, the gastrointestinal absorption of hesperidin and hesperetin as an aglycone of hesperidin after oral administration of Citrus unshiu extract (CU-ext) has not been clarified. We developed a simultaneous HPLC analysis for hesperidin and hesperetin in plasma and investigated the pharmacokinetics of hesperidin and hesperetin after oral administration of CU-ext compared with that after hesperidin solution or suspension in rats. Much higher plasma concentrations of hesperidin and hesperetin were observed after administration of CU-ext compared to those after hesperidin suspension. The maximum plasma concentration (Cmax) and bioavailability of hesperidin was 835 ng/mL and 3.5-7%, respectively, after administration of CU-ext (200 mg/kg), although respective values after hesperidin suspension were only 144 ng/mL and 0.5-1.5%. Comparison of the ratio of AUC o fhesperetin to that of hesperidin also demonstrated that a part of hesperidin was absorbed after conversion to hesperetin. This study showed that the form of CU-ext could promote the absorption of hesperidin.
  • Atsushi Kawase; Akiyuki Fujii; Makiko Negoro; Ryosuke Akai; Miki Ishikubo; Hiroshi Komura; Masahiro Iwaki
    DRUG METABOLISM AND PHARMACOKINETICS 23 3 196 - 206 2008年 
    This study aimed to clarify the differences in mRNA levels of cytochrome P450 (CYP) isoforms and nuclear receptors between Dark Agouti (DA) and Sprague-Dawley (SD) rats which are animal models for poor metabolizers and extensive metabolizers for CYP2D6, respectively. Using liver and small intestine tissues of both rat strains, we investigated the mRNA levels of CYP1A, 2A, 2B, 2C, 2D, 2E, and 3A subfamilies and nuclear receptors which regulate the transcription of CYP isoforms. In the liver, male DA rats showed a low CYP2D2 mRNA level but high mRNA levels of CYP3A1, 3A2, and 1A1 compared to SD rats. No significant difference was noted in other CYP isoforms. The mRNA levels of CAR were higher in DA rats than those in SD rats. In small intestine, the mRNA levels of CYP isoforms and nuclear receptors exhibited no significant strain differences. In addition, the activity of CYP3A in small intestinal microsome did not differ between SD and DA rats. Female DA rats exhibited higher mRNA levels of CYP3A1, 3A2, and 2B1 in the liver than female SD rats. In conclusion, the mRNA levels of CYP3A1 and 3A2 isoforms and CAR in the liver but not in the small intestines were different between DA and SD rats in both sexes.
  • Atsushi Kawase; Noriko Hirata; Masashi Tokunaga; Hideaki Matsuda; Masahiro Iwaki
    JOURNAL OF HEALTH SCIENCE 53 5 622 - 624 2007年10月 
    We investigated whether the efficiency of intestinal calcium (Ca) absorption was improved by concomitant ingestion of gum arabic (GA) in rats. We used the Ussing chamber method to clarify the effect of GA on upper and lower small intestinal absorption of Ca. Increased in vitro Ca permeation was observed in rats who ingested water with 7.5% GA for 10 days. These results suggested that administration of GA with Ca could increase the efficiency of oral Ca absorption.
  • Atsushi Kawase; You Tsunokuni; Masahiro Iwaki
    DRUG METABOLISM AND DISPOSITION 35 2 256 - 261 2007年02月 
    Nuclear receptors such as constitutive androstane receptor (CAR) and pregnane X receptor (PXR) regulate the transcription of cytochromes P450 and transporters. We investigated whether quantitative and functional changes in CAR and PXR could affect bilirubin detoxification in chronic arthritis. The CAR mRNA level was significantly decreased in the liver of mice with collagen-induced arthritis (CIA) compared with control mice. In normal mice treated with CAR agonists, relatively rapid elimination of bilirubin was observed after its intravenous injection. Next, we investigated the effects of CAR on bilirubin-detoxifying enzymes and transporters in arthritis. The mRNA levels of organic anion transporter peptide (OATP) 2, glutathione S-transferase (GST) A1, and GSTA2 were decreased in CIA mice, whereas the mRNA levels of OATP4, UDP-glucuronosyltransferase 1A1, and multidrug resistance-associated protein 2 remained unchanged. The protein levels and transport activities of OATP2 were also decreased in CIA mice. Furthermore, the CIA mice actually exhibited retarded elimination of bilirubin after its intravenous injection. These results indicate that alterations to CAR during arthritis affect the elimination of bilirubin because of changes in multiple bilirubin-detoxifying enzymes and transporters.
  • 稲森雅幸; 川瀬篤史; 岩城正宏; 古賀義久
    Med J Kinki Univ 32 4 243 - 251 近畿大学 2007年 
    塩酸デクスメデトミジン(Dex)は,重症患者の鎮静に用いられるため,低酸素血症を誘発する可能性がないことを確かめておく必要がある.そこで,肺循環への作用を明確にする目的で,家兎循環動態標本ならびに肺動脈送血,左心房脱血の定流量再潅流標本を作成し,Dexの持続投与による全身の循環動態への影響およびHPV反応に及ぼす影響を検討した.また,心臓手術後の集中治療室入室患者に対し,Dex持続投与による循環動態の変化を検討した.Dexを全身麻酔下の家兎に投与したところ,平均動脈圧(MAP)は投与初期に低下したが,平均肺動脈圧(MPAP)は変化しなかった.心拍数(HR),心拍出量(CO)は投与後速やかに減少したが,一回拍出量(SV)の減少は認められなかった.血中濃度は投与後約60分で定常状態に達すると推測された.HPV反応はDex投与により増強も減弱もしなかった.しかし,臨床使用濃度の約400倍と考えられる高濃度では肺動脈圧の上昇が認められた.心臓手術後患者に初期負荷投与を行わずDexを持続投与したところ,初期負荷投与で生じる急激な高血圧,低血圧などの循環動態の変動は認められず,60分後には鎮静レベルも良好であった.Dexは早期開始により循環動態の変動を少なくすることができ,また,HPV反応に与える影響がないため,低酸素血症を引き起こす可能性は極めて少ないものと考えられた.
  • Satoshi Uno; Atsushi Kawase; Akiko Tsuji; Tadatoshi Tanino; Masahiro Iwaki
    DRUG METABOLISM AND PHARMACOKINETICS 22 4 313 - 321 2007年 
    Adjuvant- induced arthritis (AA) rats have been used as an animal model for rheumatoid arthritis. Several studies have shown that the pharmacokinetics of a number of drugs are altered in AA rats. We investigated the effects of AA on the barrier functions of the intestine using a rat model. Intestinal CYP3A activities (midazolam 1'-hydroxylation and 7-benzyloxy-4-(trifluoromethyl)-coumarin 7-hydroxylation) in AA rats were significantly decreased compared with those in normal rats, with marked decrease observed in the upper segment of intestine. Intestinal P-glycoprotein (P-gp) activitiy at upper segment was also significantly decreased in AA rats to 60% of that in normal rats, and the other segments (middle and lower) of intestine also exhibited tendencies toward decrease in P-gp activity. This decrease was supported by the finding that levels of mdr1a mRNA and P-gp protein were decreased in AA rats. No significant diSerences were observed in intestinal paracellular and transcellular permeability between AA and normal rats. These results suggest that intestinal CYP3A and P-gp activities are decreased in AA rats, and that the pharmacokinetics and bioavailabilities of drugs whose membrane permeation is limited by intestinal CYP3A and/or P-gp may be altered in rheumatic diseases.
  • A. Kawase; I. Yoshida; Y. Tsunokuni; M. Iwaki
    XENOBIOTICA 37 4 366 - 374 2007年 
    Nuclear receptors, such as pregnane X receptor (PXR) and constitutive androstane receptor (CAR), regulate the transcription of transporters and cytochrome P450s (CYPs). We investigated whether quantitative and functional changes in PXR and CAR affected the transporters and CYPs in a mouse model of chronic arthritis. The mRNA levels of PXR were significantly decreased in the intestine of mice with collagen-induced arthritis (CIA) compared with control mice. The mRNA levels of CAR were significantly decreased in both the liver and intestine of CIA mice. The mRNA levels of Mdr1a/1b, Mrp3, BCRP and Cyp2b10 were decreased in the liver of CIA mice, while little change in the mRNA levels was observed for Cyp3a11 in the liver and the transporters in the intestine. Taken together, the present results reveal that the effects of CAR mRNA suppression on the regulation of transporters and CYPs differ between the liver and intestine in chronic arthritis.
  • Atsushi Kawase; Keiko Isaji; Ayumi Yamaoka; Naoki Kobayashi; Makiya Nishikawa; Yoshinobu Takakura
    VACCINE 24 27-28 5535 - 5545 2006年07月 
    DNA vaccination is an attractive approach with various advantages over conventional vaccination. The present study was undertaken to examine whether polyplex-based DNA vaccination could be used to modulate immune responses by plasmid DNA (pDNA). Methylated bovine serum albumin (mBSA) was used as a model of a cationic macromolecular carrier of pDNA encoding obalbumin (OVA) and the effects of polyplex formation of pDNA with mBSA on the antigen-specific immune responses were examined. Anti-OVA IgG antibody production was significantly increased following intradermal immunization with the polyplex compared with naked pDNA, although the induction of cytotoxic T lymphocyte activity was lowered by polyplex formation. We also demonstrated that the disposition and gene expression of pDNA following intradermal injection could be manipulated by polyplex formation. Intriguingly, we also found that the migration of dendritic cells to the injected site could be induced by polyplex formation probably due to a high level of tumor necrosis factor a production from the keratinocytes treated with mBSA/pDNA complexeses. Thus, the present study has demonstrated that the immune responses could be biased towards a Th2-type response by polyplex-based DNA vaccination through manipulation of not only pDNA disposition but also dendritic cell migration. (c) 2006 Elsevier Ltd. All rights reserved.
  • 川瀬 篤史; 津國 優; 岩城 正宏
    日本薬物動態学会年会講演要旨集 21 259 - 259 一般社団法人 日本薬物動態学会 2006年
  • 宇野 敏志; 浦木 美里; 川瀬 篤史; 岩城 正宏
    日本薬物動態学会年会講演要旨集 21 199 - 199 一般社団法人 日本薬物動態学会 2006年
  • H Komura; A Kawase; M Iwaki
    JOURNAL OF PHARMACEUTICAL SCIENCES 94 12 2656 - 2666 2005年12月 
    The purpose of this study was to investigate the advantages of the substrate depletion assay for evaluating linearity of pharmacokinetics compared with the metabolite formation assay. For propranolol, metoprolol, and nisoldipine with multiple and/or sequential metabolisms, the Michaelis constant (K-m) and maximum metabolic intrinsic clearance obtained from the depletion assay using rat and human liver microsomes showed a good correlation with relevant parameters with the formation assay. In vitro kinetics and in vivo pharmacokinetic profiles after oral administration of timolol, metoprolol, and propranolol, were investigated in rats using the depletion assay. The same rank order was found between nonlinearities based on dose-normalized areas under the plasma concentration curve (AUC/Dose) and K-m values. Using the kinetic parameters of these compounds, AUC was predicted based on a physiological based pharmacokinetic model incorporated saturable metabolism. The AUCs predicted for propranolol and metoprolol had a good relationship with those observed in the in vivo studies, implying that the depletion assay could be useful for assessing linearity of pharmacokinetics. (c) 2005 Wiley-Liss, Inc. and the American Pharmacists Association.
  • A Kawase; N Kobayashi; K Isaji; M Nishikawa; Y Takakura
    INTERNATIONAL JOURNAL OF PHARMACEUTICS 293 1-2 291 - 301 2005年04月 
    To modulate the immune responses of DNA vaccine, it is very important to control the disposition and gene expression of plasmid DNA (pDNA) after local administration. We chose methylated bovine serum albumin (mBSA), a cationic macromolecule, as a carrier of pDNA. We examined the effects of complexation of pDNA with mBSA on the disposition and gene expression in mice after intramuscular administration. The elimination from injection site was retarded and the accumulation to lymph nodes was increased at the positively charged mBSA/pDNA complexes. As the charge ratios of mBSA/pDNA complexes were higher, the levels of gene expression were reduced. Antigen specific immune responses were evaluated using pDNA encoding ovalbumin (OVA), pCMV-OVA, as a model antigen-expressing pDNA. However, significant levels of production of anti-ovalbumin IgG antibody were obtained in mice immunized with a positively charged complex, mBSA/pCMV-OVA (8:1) (weight ratio). In vitro experiments using DC2.4 cells, a murine dendritic cell line, demonstrated that the levels of gene expression and cytokine release were increased by complexation. These results suggest that the immune responses might be manipulated by complexation presumably due to the altered disposition and gene expression of pDNA. (c) 2005 Elsevier B.V. All rights reserved.
  • N Kobayashi; K Hirata; S Chen; A Kawase; M Nishikawa; Y Takakura
    JOURNAL OF GENE MEDICINE 6 4 455 - 463 2004年04月 
    Background A large-volume intravenous (i.v.) injection of DNA, i.e. a hydrodynamics-based transfection procedure, is known to be an efficient and liver-specific method of in vivo gene delivery. However, little is available on an applicable particle size in the procedure. Methods We examined the effect of particle size on the hepatic delivery by the hydrodynamics-based procedure, using fluorescein isothiocyanate labeled polystyrene microspheres (MS) of 50, 200 or 500 nm in diameter. MS were injected intravenously to mice by a conventional (normal) or the hydrodynamics-based procedure and their degree of hepatic uptake was determined fluorometrically. Results For all sizes tested, the two procedures were similar in terms of the apparent degree of hepatic uptake, whereas the intrahepatic localization of MS was apparently different between the procedures as shown by an examination of frozen tissue sections. In mice with gadolinium chloride induced Kupffer cell blockade, the hepatic uptake of MS following the normal procedure was decreased while that of the hydrodynamics-based procedure was less affected. This phenomenon of enhanced hepatic delivery seemed to be more effective for larger particles. Confocal microscopic observation of hepatocyte suspensions indicated that part of the injected MS-50 was delivered intracellularly following the hydrodynamics-based procedure, whereas almost all the observed MS-200 and MS-500 were detected in the extracellular compartment or on the surface of the cells. This was supported by the fact that most of the injected MS existed pericellularly around the transgene-expressing cells. Conclusions The hydrodynamics-based procedure facilitated extravasation and hepatic delivery of MS. Larger MS were more efficiently extravasated and trapped by the liver, whereas intracellular delivery hardly occurred with them. Copyright (C) 2004 John Wiley Sons, Ltd.
  • N Kobayashi; Y Matsui; A Kawase; K Hirata; M Miyagishi; K Taira; M Nishikawa; Y Takakura
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 308 2 688 - 693 2004年02月 
    RNA interference (RNAi) induced by delivery of a small-interfering RNA (siRNA)-expressing vector was characterized in mice. siRNA-expressing plasmid DNA (pDNA) was injected by a hydrodynamics-based procedure along with pDNA encoding an exogenous target luciferase gene. A comparative study showed that stem-loop-type siRNA-expressing pDNA was superior, in terms of the transgene suppressive efficacy, to the tandem-type in the liver following systemic delivery of these pDNAs. Transgene suppression occurred in the liver, kidney, and lung as well as muscle. The degree of suppression was dependent on the dose of siRNA-expressing pDNA and the time at which transgene expression was determined following simultaneous injection of siRNA-expressing and target pDNAs. A reduction in transgene expression became apparent at 1 day after injection, whereas a lower degree of inhibition was obtained before this, as early as 6 h even in mice treated with an excess of siRNA-expressing pDNA. These results suggest that delivery of siRNA-expressing pDNA requires a period of time for induction of RNAi. A study of sequential injections revealed that prior injection of siRNA-expressing pDNA produced a significant suppression for at least 1 day, which disappeared within 4 days. Confocal microscopic studies indicated that the localization of the cells with successful delivery of transgene was different between primary and secondary hydrodynamics-based injections, accounting for the less effective inhibition following the sequential injections. Taken together, these results demonstrate that vector-based in vivo RNAi is a dose- and time-dependent process and offers the possibility of suppressing endogenous targets in a variety of somatic cells.
  • A Kawase; T Nomura; K Yasuda; N Kobayashi; M Hashida; Y Takakura
    JOURNAL OF PHARMACEUTICAL SCIENCES 92 6 1295 - 1304 2003年06月 
    Previous studies have suggested that direct injection of naked plasmid DNA (pDNA) into solid tumors can be a useful method for in vivo gene transfer into tumor cells. To gain more insight into this approach, we studied the disposition and gene expression characteristics of naked pDNA after intratumoral injection by direct comparison with those after intramuscular injection in mice. pDNA encoding reporter genes were directly injected into subcutaneous solid tumor models and skeletal muscles. Biodistribution studies using radiolabeled pDNA showed that the elimination of pDNA from the injection site was relatively fast and a part of the pDNA was absorbed from the lymphatic system after both local injections. Confocal microscopic studies using fluorescein-labeled pDNA demonstrated that pDNA distributed efficiently throughout the muscle tissue whereas pDNA localization in the tumor tissue was restricted. Characterization of gene expression clarified the variation in expression level between tumor preparations and some factors affecting the expression level in the tumor. Reporter gene expression was significantly inhibited by simultaneous administration of some polyanions in both cases, suggesting that a specific mechanism may be involved in the naked pDNA uptake by muscle and tumor cells. These findings provide useful information for direct naked pDNA delivery into solid tumors. (C) 2003 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm.

講演・口頭発表等

  • アセトアミノフェン誘発性肝障害に対するPGE2不活化酵素15-PGDH阻害の影響
    島田絋明; 横飛暉斗; 高田万桜; 川瀬篤史; 岩城正宏
    日本薬学会第143年会 2023年
  • 定型抗精神病薬pimozideの構造展開により開発した新規T型Ca2+チャネル阻害薬KTtp38: チャネル選択性, 電気生理学的特徴, 鎮痛活性の評価
    笠波嘉人; 高島康宏; 木野貴博; 石川千浩; 長南百香; 豊岡尚樹; 関口富美子; 坪田真帆; 川瀬篤史; 大久保つや子; 吉田 繁; 岡田卓哉; 川畑篤史
    第96回日本薬理学会年会 2022年
  • The regulation of hepatic prostaglandin E2 amount and its effect on acetaminophen-induced liver injury through improving endothelial damages
    横飛暉斗; 島田紘明; 吉川幸伽; 山本望乃花; 川瀬篤史; 岩城正宏
    日本薬物動態学会第37回年会 2022年
  • The Hydrolysis of Acyl Glucuronides in Human and Rat Liver Microsomes
    生田博之; 島田紘明; 阪本健次郎; 中村令奈; 川瀬篤史; 松野純男; 岩城正宏
    日本薬物動態学会第37回年会 2022年
  • Simultaneous quantification of eicosanoids produced in the liver S9 fractions
    島田紘明; 竹田祐佳; 川瀬篤史; 岩城正宏
    日本薬物動態学会第37回年会 2022年
  • アセトアミノフェン誘発性血管内皮傷害に対するプロスタグランジンE2の抑制作用
    山本望乃花; 島田紘明; 横飛暉斗; 川瀬篤史; 岩城正宏
    第72回日本薬学会関西支部総会・大会 2022年
  • HepG2細胞とTHP-1細胞由来マクロファージとの共培養におけるNSAIDsによる細胞傷害の変動
    柏木理佐; 川瀬篤史; 田中さつき; 高島桜花; 島田紘明; 岩城正宏
    第72回日本薬学会関西支部総会・大会 2022年
  • NSAIDsアシルグルクロニドのUGT1A9およびUGT2B7活性に対する影響
    湯山博司; 川瀬篤史; 岡祐里奈; 吉川真白; 吉里 翼; 島田紘明; 岩城正宏
    第72回日本薬学会関西支部総会・大会 2022年
  • 炎症モデルマウスにおけるGSH輸送トランスポーターSlc25a39/40の発現および機能変動
    畑中もも子; 川瀬篤史; 松田尚也; 首藤礼華; 島田紘明; 岩城正宏
    第72回日本薬学会関西支部総会・大会 2022年
  • 芳香族L-アミノ酸脱炭酸酵素を阻害しないD-carbidopaはH2S産生酵素cystathionine-β-synthaseを阻害することでTNBS誘起結腸痛を抑制する
    井場祐里子; 本夛泉侑; 坪田真帆; 川瀬篤史; 岡田卓哉; 豊岡尚樹; 川畑篤史
    第141回日本薬理学会近畿部会 2022年
  • 炎症モデルマウスにおけるグルタチオン輸送トランスポーターSlc25a39/40発現および機能変動
    川瀬篤史; 畑中もも子; 松田尚也; 首藤礼華; 島田紘明; 岩城正宏
    第49回日本毒性学会 2022年
  • ヒト肝ミクロソーム中におけるアシルグルクロン酸抱合体の加水分解特性
    島田紘明; 生田博之; 阪本健次郎; 中村令奈; 川瀬篤史; 松野純男; 岩城正宏
    日本薬剤学会第37年会 2022年
  • Ilex Latifolia葉抽出物の食後血統上昇抑制作用
    笹井剛一; 島田紘明; 上野省一; 川瀬篤史; 森川敏生; 岩城正宏
    日本薬学会第142年会 2022年
  • Acetaminophen誘発性肝障害に対する15-hydroxyprostaglandindehydrogenase阻害の影響
    横飛暉斗; 島田紘明; 吉川幸伽; 山本望乃花; 川瀬篤史; 岩城正宏
    日本薬学会第142年会 2022年
  • LPS投与による炎症モデルマウスにおける肝臓と腎臓のトランスポーター発現変動に対するHMGB1の役割
    松田尚也; 川瀬篤史; 入江浩太; 髙井柚希; 島田紘明; 岩城正宏
    日本薬学会第142年会 2022年
  • 肝ミクロソーム中における非ステロイド性抗炎症薬のアシルグルクロン酸抱合体の加水分解特性
    阪本健次郎; 島田紘明; 生田博之; 川瀬篤史; 岩城正宏
    日本薬学会第142年会 2022年
  • 芳香族Lアミノ酸脱炭酸酵素阻害薬カルビドパはH2S産生酵素cystathionine-β-synthaseを阻害することで内臓痛を抑制する
    井場祐里子; 本夛泉侑; 坪田真帆; 川瀬篤史; 岩城正宏; 川畑篤史
    第71回日本薬学会関西支部 2021年
  • 非ステロイド性抗炎症薬のアシルグルクロン酸抱合体のラットおよびヒト肝ミクロソーム中における加水分解
    生田博之; 島田紘明; 川瀬篤史; 岩城正宏
    第71回日本薬学会関西支部 2021年
  • 四塩化炭素およびアセトアミノフェン誘発性肝障害における肝プロスタグランジンE2量調節機構
    島田紘明; 横飛暉斗; 山田 爽; 川瀬篤史; 岩城正宏
    第71回日本薬学会関西支部 2021年
  • LPS誘発炎症モデルマウスの肝臓および腎臓におけるトランスポーター変動におけるHMGB1の役割
    髙井柚希; 川瀬篤史; 入江浩太; 松田尚也; 島田紘明; 岩城正宏
    第71回日本薬学会関西支部 2021年
  • NSAIDsアシルグルクロン酸抱合体と肝臓内タンパク質の共有結合体生成における立体選択性
    岡祐里奈; 川瀬篤史; 山下莉央; 吉里 翼; 吉川真白; 島田紘明; 岩城正宏
    第71回日本薬学会関西支部 2021年
  • Diclofenacによる細胞傷害に対するHepG2とTHP-1の接触型および非接触型共培養の影響
    田中さつき; 川瀬篤史; 高島桜花; 島田紘明; 岩城正宏
    第71回日本薬学会関西支部 2021年
  • NHERF1/EBP50を標的とした排出トランスポーターの機能調節
    川瀬篤史; 小山勇之介; 深江彩加; 首藤礼華; 島田紘明; 岩城正宏
    第71回日本薬学会関西支部 2021年
  • Acetaminophen誘発性肝障害におけるprostaglandin E2量調節機構とその役割
    横飛暉斗; 島田紘明; 吉川幸加; 川瀬篤史; 岩城正宏
    第63回日本脂質生化学会 2021年
  • LPSラットにおけるジフェンヒドラミン投与時の脳移行性の変動
    中馬泰平; 川瀬篤史; 入江浩太; 松田尚也; 覚野明日香; 島田紘明; 岩城正宏
    日本薬学会関西支部大会第70年会 2020年
  • NSAIDsアシルグルクロン酸抱合体のグルクロン酸転移酵素に対する立体選択的な共有結合体生成
    山下莉央; 川瀬篤史; 高島桜花; 吉里 翼; 島田紘明; 岩城正宏
    日本薬学会関西支部大会第70年会 2020年
  • Carbamazepine誘発性肝障害における肝prostaglandin E2量調節機構
    大場憲一; 島田紘明; 橋本凌汰; 川瀬篤史; 岩城正宏
    日本薬学会関西支部大会第70年会 2020年
  • Acetaminophen誘発性肝障害における肝Prostaglandin E2量調節機構とその意義
    横飛暉斗; 島田紘明; 吉川幸伽; 川瀬篤史; 岩城正宏
    日本薬学会関西支部大会第70年会 2020年
  • 薬物誘発性肝障害における肝プロスタグランジンE2量調節機構
    大場憲一; 島田紘明; 吉川幸伽; 山田 爽; 川瀬篤史; 岩城正宏
    第62回日本脂質生化学会 2020年
  • マウスにおけるシトクロムP450誘導過程におけるプロテインキナーゼNファミリーの役割
    川瀬篤史; 向井秀幸; 立石駿介; 黒田真太郎; 松田尚也; 佐藤亮介; 島田紘明; 杉浦麗子; 岩城正宏
    日本薬学会第140年会 2020年
  • In situ肝還流法によるジクロフェナクの肝毒性評価
    清水佑里子; 島田紘明; 藤原麻由; 川瀬篤史; 岩城正宏
    日本薬学会第140年会 2020年
  • Lipopolysaccharide投与ラットにおけるdiphenhydramine脳移行性の変動
    中馬泰平; 川瀬篤史; 入江浩太; 覚野明日香; 松田尚也; 島田紘明; 岩城正宏
    日本薬学会第140年会 2020年
  • 肝細胞とマクロファージの共培養系を用いたジクロフェナク誘発性細胞傷害の評価
    山下莉央; 川瀬篤史; 高島桜花; 吉里 翼; 島田紘明; 岩城正宏
    日本薬学会第140年会 2020年
  • Diclofenac-induced cytotoxicity in hepatocytes co-cultured with macrophages
    Kawase A; Yamashita R; Takashima O; Kaneto A; Shimada H; Iwaki M
    79th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2019年
  • The regulatory mechanism of hepatic PGE2 disposition in carbamazepine-induced liver injury
    Iwaki M; Shimada H; Hashimoto R; Oba K; Kawase A
    IUTOX 15th International Congress of Toxicology 2019年
  • The role of OATP2A1 in hepatoprotection against CCl4-induced liver injury
    Shimada H; Hashimoto R; Aoki A; Yamada S; Kawase A; Iwaki M
    IUTOX 15th International Congress of Toxicology 2019年
  • アジュバント関節炎ラットにおける塩基性薬物の脳移行性について
    風岡顯良; 川瀬篤史; 島田紘明; 岩城正宏
    日本薬剤学会第34年会 2019年
  • カンカニクジュヨウ中主成分エキナコシド,アクテオシドのSGLT1阻害活性およびSGLT1介在性輸送
    羽渕風雅; 島田紘明; 岡本雄平; 川瀬篤史; 李 征; 村岡 修; 岩城正宏
    日本薬剤学会第34年会 2019年
  • 非ステロイド性抗炎症薬のアシルグルクロン酸抱合体生成に対するCa2+およびMg2+の促進作用
    島田紘明; 清水佑里子; 濵口健斗; 藤本和佳; 川瀬篤史; 岩城正宏
    日本薬剤学会第34回年会 2019年
  • 非ステロイド性抗炎症薬のアシルグルクロン酸抱合体生成・分解パラメータによる毒性予測の可能性
    熊澤佳亮; 島田紘明; 野見真人; 塩尻眞弓; 川瀬篤史; 岩城正宏
    日本薬剤学会第34回年会 2019年
  • ジクロフェナクのグルクロン酸抱合に与えるCaおよびMgの影響
    清水佑里子; 島田紘明; 濵口健斗; 川瀬篤史; 岩城正宏
    未来創薬医療イノベーションシンポジウム 2019年
  • 抗がん薬デリバリー効率の改善を目指して ~トランスポーター裏打ちタンパク質の調節を利用したトランスポーター発現低下への試み~
    廣底美保; 川瀬篤史; 井上裕太; 杉原由華; 小山勇之介; 島田紘明; 岩城正宏
    未来創薬医療イノベーションシンポジウム 2019年
  • 肝臓でのシトクロムP450誘導過程におけるプロテインキナーゼNの関与
    立石駿介; 川瀬篤史; 向井秀幸; 黒田真太郎; 佐藤亮介; 島田紘明; 岩城正宏; 杉浦麗子
    未来創薬医療イノベーションシンポジウム 2019年
  • カルバマゼピン誘発性肝障害におけるProstaglandinE2動態調節
    大場憲一; 島田紘明; 橋本凌汰; 川瀬篤史; 岩城正宏
    未来創薬医療イノベーションシンポジウム 2019年
  • カルバマゼピン誘発性肝障害における肝プロスタグランジンE2動態調節機構
    大場憲一; 島田紘明; 橋本凌汰; 川瀬篤史; 岩城正宏
    日本薬学会第139年会 2019年
  • トランスポーター裏打ちタンパク質を利用した抗がん薬デリバリー効率の改善
    川瀬篤史; 井上裕太; 廣底美保; 杉原由華; 島田紘明; 岩城正宏
    日本薬学会第139年会 2019年
  • 四塩化炭素誘発性肝障害におけるOATP2A1の役割
    島田紘明; 橋本凌汰; 青木 彩; 川瀬篤史; 岩城正宏
    日本薬学会第139年会 2019年
  • Modulation of transporter activities in hepatocytes and cancer cells by knockdown of transporter-associated proteins  [通常講演]
    川瀬篤史
    The 2nd Workshop for Korea-Japan Young Scientists on Pharmaceutics 2018年07月
  • Alteration of hepatic prostaglandin E2-related gene expression under liver injury condition
    Hiroaki Shimada; Ryota Hashimoto; Sachika Yoshikawa; Masaya Nakahama; Atsushi Kawase; Masahiro Iwaki
    59th International Conference on the Bioscience of Lipids 2018年
  • 非ステロイド性抗炎症薬のアシルグルクロン酸抱合体生成に対するCaおよびMgの影響
    島田紘明; 濵口健斗; 清水佑里子; 藤本和佳; 川瀬篤史; 岩城正宏
    第68回日本薬学会近畿支部総会・大会 2018年
  • Modulation of transporter activities in cancer cells by transporter-associated proteins
    Atsushi Kawase; Yuta Inoue; Miho Hirosoko; Hiroaki Shimada; Masahiro Iwaki
    2018 MDO/JSSX 2018年
  • Impact of Ca2+ and Mg2+ depletion on glucuronidation of diclofenac
    Hiroaki Shimada; Kento Hamaguchi; Yuriko Shimizu; Atsushi Kawase; Masahiro Iwaki
    2018 MDO/JSSX 2018年
  • Brain distribution of diphenhydramine via transporters decrease in adjuvant-induced arthritic rats
    Akira Kazaoka; Atsushi Kawase; Hiroaki Shimada; Masahiro Iwaki
    2018 MDO/JSSX 2018年
  • カンカニクジュヨウ中主成分エキナコシド,アクテオシドのグルコース/Na+共輸送トランスポーター阻害作用  [通常講演]
    島田紘明; 卜部裕一; 岡本雄平; 川瀬篤史; 李 征; 森川敏生; 村岡 修; 岩城正宏
    日本生薬学会第64回年会 2017年
  • 病態時のトランスポーター変動と特異体質性肝障害発症機序の解明  [通常講演]
    川瀬篤史
    病態情報薬学分野設立20周年記念講演会 2017年
  • マウス肝細胞-腹腔マクロファージ共培養系におけるグルタチオン枯渇のジクロフェナク毒性に対する影響  [通常講演]
    川瀬篤史; 金藤彩加; 石橋真央; 小林諒裕; 中村 暉; 島田紘明; 岩城正宏
    第44回日本毒性学会学術年会 2017年
  • 薬物誘発性肝障害に伴う肝プロスタグランジンE2動態変動  [通常講演]
    橋本凌汰; 島田紘明; 東田千代; 青木 彩; 川瀬篤史; 岩城正宏
    第59回日本脂質生化学会 2017年
  • Correlation between Formation of Glucuronide Metabolite and Covalent Protein Adducts of Nonsteroidal Anti-inflammatory Drugs  [通常講演]
    Hiroaki Shimada; Atsushi Kawase; Taro Ogiso; Masahiro Iwaki
    Pharmaceutical Sciences World Congress 2017 2017年
  • Effects of Glutathione Depletion on Diclofenac-induced Cytotoxicity in Mouse Hepatocytes  [通常講演]
    Atsushi Kawase; Ayaka Kaneto; Mao Ishibashi; Hiroaki Shimada; Masahiro Iwaki
    Pharmaceutical Sciences World Congress 2017 2017年
  • Effect of Hepatic and Renal Functions of Pharmacokinetics of Naproxen in Guinea Pigs: Acyl Glucuronide Concentration and Irreversible Binding to Plasma Protein  [通常講演]
    Masahiro Iwaki; Taro Ogiso; Hiroaki Shimada; Atsushi Kawase
    Pharmaceutical Sciences World Congress 2017 2017年
  • 能動的学習を促す双方向授業方法の検討と学習効果 -総合演習科目へのレスポンスアナライザーの導入-  [通常講演]
    大内秀一; 松野純男; 伊藤栄次; 川?直人; 川瀬篤史; 岩城正宏
    第1回日本薬学教育学会大会 2016年
  • Protein Kinase N Family-dependent Regulation of Hepatic Cytochrome P450 2C in Mice  [通常講演]
    Atsushi Kawase; Nobuyuki Nimura; Marina Yamashita; Yuki Ono; Koji Kubouchi; Nanae Sawada; Hiroaki Shimada; Ryosuke Satoh; Ayako Kita; Hideyuki Mukai; Masahiro Iwaki; Reiko Sugiura
    日本薬物動態学会第31回年会 2016年
  • Stability of Echinacoside and Acteoside, Components of Cistance Tubulosa, in Gastrointestinal Tract and Liver  [通常講演]
    Hiroaki Shimada; Yuichi Urabe; Yuhei Okamoto; Mayumi Komura; Yuki Yamashita; Atsushi Kawase; Toshio Morikawa; Osamu Muraoka; Masahiro Iwaki
    日本薬物動態学会第31回年会 2016年
  • Effect of ERM Protein Function Depression on ABC Transporter Activities  [通常講演]
    Yuta Inoue; Atsushi Kawase; Sayaka Nakazaki; Erika Koizumi; Hiroaki Shimada; Masahiro Iwaki
    日本薬物動態学会第31回年会 2016年
  • Involvement of Reactive Metabolites of Diclofenac in Cytotoxicity in Sandwich Cultured Rat Hepatocytes  [通常講演]
    Ryota Hashimoto; Atsushi Kawase; Mai Shibata; Hiroaki Shimada; Masahiro Iwaki
    日本薬物動態学会第31回年会 2016年
  • 多糖類を主成分とするとろみ調整剤からのグルコース生成に関する基礎的研究  [通常講演]
    松浦正佳; 岸本理咲; 加治工衛; 前田智昭; 大鳥 徹; 川瀬篤史; 島田紘明; 岩城正宏
    第10回日本薬局学会学術総会 2016年
  • Protein Kinase N (PKN) Family-dependent Regulation of Hepatic Cytochrome P450 2C and Metabolic Profile Analysis in PKN Mutant Mice through Targeted Metabolomics by LC-MS/MS  [通常講演]
    Atsushi Kawase; Nobuyuki Nimura; Marina Yamashita; Yuki Ono; Koji Kubouchi; Nanae Sawada; Hiroaki Shimada; Ryosuke Satoh; Ayako Kita; Hideyuki Mukai; Masahiro Iwaki; Reiko Sugiura
    第12回プロテインホスファターゼ国際カンファレンス 2016年
  • Influence of Radicin Knockdown on Drug Efflux Transporters of Cancer Cells  [通常講演]
    Yuta Inoue; Atsushi Kawase; Sayaka Nakazaki; Erika Koizumi; Hiroaki Shimada; Masahiro Iwaki
    第12回プロテインホスファターゼ国際カンファレンス 2016年
  • Contribution of Human Hepatic Cytochrome P450 Isoforms to the Stereoselective Oxidation of Carvedilol  [通常講演]
    Masahiro Iwaki; Saya Bandoh; Atsushi Kawase; Hiroshi Komura; Toshiro Niwa
    日本薬物動態学会第30回年会 2015年
  • Inhibitory Effects of Pravastatin on the Expression of Intestinal Niemann-pick C1 Like 1  [通常講演]
    Atsushi Kawase; Seiji Hata; Mai Takagi; Masahiro Iwaki
    日本薬物動態学会第30回年会 2015年
  • Protein Kinase Nファミリー遺伝子改変マウスを用いた薬物代謝酵素の解析  [通常講演]
    小野祐輝; 窪内康二; 木戸友絵; 澤田奈々; 二村信之; 山下真理奈; 川瀬篤史; 岩城正宏; 向井秀幸; 喜多綾子; 佐藤亮介; 杉浦麗子
    第65回日本薬学会近畿支部総会・大会 2015年
  • 炎症時におけるトランスポーター変動とERMタンパク質の関連  [通常講演]
    川瀬篤史
    第64回日本薬学会近畿支部総会・大会 2014年
  • Alterations in Expression and Function of ABC Transporters and ERM Proteins in Inflammation  [通常講演]
    Atsushi Kawase
    Global Education Seminar West 2014 2014年
  • Alterations in Expression and Function of ABC Transporters and ERM Proteins in Adjuvant-induced Arthritis Rats  [通常講演]
    Atsushi Kawase; Masahiro Iwaki
    Anti-Aging International Mini-Symposium 2014 2014年
  • Development for Hemiacetal Ester of New Quinolone Avoiding Chelation with Metal Containing Drugs, Together with Avoiding Pseudomembranous Colitis  [通常講演]
    Kenji Matsuyama; Tohru Ohtori; Atsushi Kawase; Masahiro Iwaki; Tetsutaro Kimachi; Yoshikazu Ishii
    19th North American Regional ISSX Meeting and 29th JSSX Meeting 2014年
  • Alterations in Expression and Function of Ezrin/radixin/moesin Proteins for Transporters in Adjuvant-induced Arthritis Rats  [通常講演]
    Masahiro Iwaki; Atsushi Kawase; Misato Sakata; Misaki Nakasaka; Yukio Kato
    19th North American Regional ISSX Meeting and 29th JSSX Meeting 2014年
  • アジュバント関節炎ラットにおけるABCトランスポーター発現変動  [通常講演]
    足立満実子; 川瀬篤史; 岩城正宏
    日本薬学会第133年会 2013年
  • 炎症時におけるERMタンパク質発現変動  [通常講演]
    矢田凪沙; 阪田美里; 足立満実子; 川瀬篤史; 加藤将夫; 岩城正宏
    第8回トランスポーター研究会年会 2013年
  • Concentration-independent Contribution of Human Hepatic Cytochrome P450 Isoforms to the Stereoselective Metabolism of Carvedilol  [通常講演]
    Masahiro Iwaki; Saya Bandoh; Megumi Itoh; Yukiko Nakamura; Hitomi Hirose; Toshiro Niwa; Hiroshi Komura; Tadatoshi Tanino; Atsushi Kawase
    日本薬物動態学会第28回年会 2013年
  • Alterations in Hepatic ABC Transporters and ERM Proteins in Adjuvant-induced Arthritis  [通常講演]
    Nagisa Yada; Misato Sakata; Atsushi Kawase; Yukio Kato; Masahiro Iwaki
    American Association of Pharmaceutical Scientists 2013 2013年
  • Effects of Adjuvant-induced Inflammation on Disposition of Diclofenac and Diclofenac Metabolites in Perfused Rat Liver  [通常講演]
    Misato Uraki; Hiroyuki Sayama; Atsushi Kawase; Yuka Matsushima; Hiroshi Komura; Masahiro Iwaki
    American Association of Pharmaceutical Scientists 2013 2013年
  • Effects of Pravastatin and Ezetimibe on the Expression of Intestinal Niemann-pick C1 Like 1 and ABCG5/G8  [通常講演]
    Atsushi Kawase; Seiji Hata; Mai Takagi; Masahiro Iwaki
    American Association of Pharmaceutical Scientists 2013 2013年
  • 高コレステロール時におけるNPC1L1発現とラット・マウス間種差  [通常講演]
    川瀬篤史; 荒木康羽; 植田元子; 瀬谷佳子; 秦 誠治; 中崎紗也香; 岩城正宏
    日本薬学会第132年会 2012年
  • 脂質異常症または絶食時におけるトランスポーター変動とプラバスタチン肝内動態に関する検討  [通常講演]
    川瀬篤史; 半田亜由美; 篠原広樹; 岩城正宏
    第7回トランスポーター研究会 2012年
  • 紅参含有ジンセノサイドのコレステロール代謝酵素CYP7Aに対する発現促進作用  [通常講演]
    川瀬篤史; 村田和也; 寒川慶一; 松田秀秋; 岩城正宏
    日本薬学会近畿支部第62回総会・大会 2012年
  • Stereoselective Contribution of Human Hepatic Cytochrome P450 Isoforms to the Metabolism of Carvedilol  [通常講演]
    Hitomi Hirose; Megumi Itoh; Hiroshi Komura; Tadatoshi Tanino; Atsushi Kawase; Masahiro Iwaki
    日本薬物動態学会第27回年会 2012年
  • エノキサシンキレート子のピボキシルエステル化による金属含有制酸剤併用時の血中エノキサシン濃度への影響  [通常講演]
    沖吉慶子; 今仲 洸; 大鳥 徹; 藤本脩太; 岡本佳世; 瀬川雅彦; 西脇敬二; 川瀬篤史; 岩城正宏; 松山賢治
    日本薬学会第131年会 2011年
  • 高脂肪食摂取および絶食ラットにおけるプラバスタチンの肝内動態への影響  [通常講演]
    半田亜由美; 川瀬篤史; 岩城正宏
    日本薬剤学会第26年会 2011年
  • メトトレキサートと非ステロイド系抗炎症薬の相互作用:非ステロイド系抗炎症薬のグルクロン酸抱合体のMRP2および4に対する輸送阻害作用  [通常講演]
    岩城正宏; 山本泰希; 半田亜由美; 川瀬篤史
    医療薬学フォーラム2011 2011年
  • Stereoselective Inhibitory Effects of Glucuronides of Nonsteroidal Anti-inflammatory Drugs on the Transport Mediated by Multiple Resistance-associated Protein (MRP) 2 and MRP4  [通常講演]
    Masahiro Iwaki; Taiki Yamamoto; Ayumi Handa; Atsushi Kawase
    BioMedical Transporters 2011 2011年
  • Alterations in P-glycoprotein in Intestine, Liver, Brain, and Kidney of the Adjuvant Arthritis Rat  [通常講演]
    Atsushi Kawase; Sari Norikane; Masahiro Iwaki
    BioMedical Transporters 2011 2011年
  • CYP2D遺伝的欠損DAラットにおけるカルベジロールのin vitroおよびin vivo立体選択的代謝  [通常講演]
    田中裕之; 寺口和宏; 廣瀬仁美; 大城 巧; 川瀬篤史; 岩城正宏
    第61回日本薬学会近畿大部総会・大会 2011年
  • 学生のニーズ把握と具体的な問題解決手法の修得を目的とした学生ワークショップの試み  [通常講演]
    安原智久; 川?直人; 八木秀樹; 川瀬篤史; 伊藤栄次; 大鳥 徹; 和田哲幸; 松山賢治; 岩城正宏
    日本薬学会第130年会 2010年
  • 紅蔘エキスの脂質代謝に関わるチトクロムP450およびトランスポーターに対する影響  [通常講演]
    川瀬篤史; 蒲生悠子; 田原知佳; 山田彩乃; 山下友希; 寒川慶一; 竹下文章; 村田和也; 松田秀秋; 岩城正宏
    日本薬剤学会第25年会 2010年
  • アジュバント関節炎発症ラットにおけるトランスポーターの変動  [通常講演]
    赤井亮介; 川瀬篤史; 法兼沙理; 岡本怜也; 岩城正宏
    日本薬剤学会第25年会 2010年
  • ラット肝臓および小腸におけるチトクロムP450とP-糖タンパク質の誘導に対するフェニトイン投与期間の影響  [通常講演]
    田中裕之; 川瀬篤史; 廣瀬仁美; 山崎和哉; 大鳥 徹; 岩城正宏
    日本薬剤学会第25年会 2010年
  • 薬学部4年制課程から6年制課程への移行に伴う本学学生の就職意識動向調査  [通常講演]
    川瀬篤史; 長井紀章; 木下充弘; 関口富美子; 桑島 博; 鈴木茂生; 西田升三; 松尾圭造; 掛樋一晃
    医療薬学フォーラム2010 2010年
  • 調剤薬局における薬剤師需要の動向予測に関する研究  [通常講演]
    長井紀章; 川瀬篤史; 木下充弘; 関口富美子; 桑島 博; 鈴木茂生; 西田升三; 松尾圭造; 掛樋一晃
    医療薬学フォーラム2010 2010年
  • 高用量レボフロキサシンの薬物動態を検討した血液透析症例  [通常講演]
    浦田元樹; 太田美由希; 北村芳子; 稲荷場ひろみ; 岡村幹夫; 川瀬篤史; 岩城正宏
    第55回日本透析医学会 2010年
  • 血液透析患者におけるレボフロキサシンの薬物動態の検討  [通常講演]
    太田美由希; 浦田元樹; 北村芳子; 崔 吉永; 岡村幹夫; 稲荷場ひろみ; 根来伸夫; 川瀬篤史; 岩城正宏
    第75回大阪透析研究会 2010年
  • エノキサシンキレート子のピボキシルエステル化による金属含有制酸剤併用時の血中エノキサシン濃度への影響  [通常講演]
    今仲 洸; 大鳥 徹; 沖吉慶子; 岡本佳世; 瀬川雅彦; 西脇敬二; 川瀬篤史; 岩城正宏
    第20回日本医療薬学会 2010年
  • 血液透析患者における高用量レボフロキサシン薬物動態の検討  [通常講演]
    太田美由希; 浦田元樹; 北村芳子; 崔 吉永; 岡村幹夫; 根来伸夫; 川瀬篤史; 岩城正宏
    第20回日本医療薬学会 2010年
  • The Effect of Fasting and Hyperlipidemia on the Disposition of Pravastatin in the In Situ Perfused Rat Liver Model  [通常講演]
    Masahiro Iwaki; Ayumi Handa; Atsushi Kawase
    Pharmaceutical Sciences World Congress 2010 2010年
  • Effects of Mrp2- and Mrp3-knockdown in Mice on Covalent Adduct Formation of Acyl Glucuronide Using shRNA-expressing Adenovirus Vector  [通常講演]
    Atsushi Kawase; Ayano Yamada; Taiki Yamamoto; Sayaka Tomatsu; Masahiro Iwaki
    Pharmaceutical Sciences World Congress 2010 2010年
  • アジュバント関節炎発症時における肝臓,小腸および脳のトランスポーターmRNA変動  [通常講演]
    宇野敏志; 浦木美里; 川瀬篤史; 岩城正宏
    日本薬学会第129年会 2009年
  • Changes in mRNA Expression of ABC and SLC Transporters in Liver and Intestines of the Adjuvant-induced Arthritis Rat  [通常講演]
    Satoshi Uno; Misato Uraki; Ayano Yamada; Atsushi Kawase; Masahiro Iwaki
    69th International Congress of FIP 2009年
  • Differences in Cytochrome P450 and Nuclear Receptor mRNA Levels in Liver and Small Intestines between SD and DA Rats  [通常講演]
    Atsushi Kawase; Akiyuki Fujii; Ryosuke Akai; Masahiro Iwaki
    69th International Congress of FIP 2009年
  • 紅蔘エキスの脂質代謝に関わるシトクロムP450およびトランスポーターに対する影響  [通常講演]
    山田彩乃; 竹下文章; 蒲生悠子; 田原知佳; 寒川慶一; 村田和也; 松田秀秋; 川瀬篤史; 岩城正宏
    第59回日本薬学会近畿支部総会・大会 2009年
  • ラットおよびマウスにおけるBCRPを介したニトロフラントイン体内動態に対するChrysinの影響  [通常講演]
    川瀬篤史; 岩城正宏
    第3回食品薬学シンポジウム 2009年
  • ラット肝臓および小腸におけるCYP3AとP糖タンパク質の誘導に対するフェニトイン投与期間の影響  [通常講演]
    大鳥 徹; 岡亜沙美; 川瀬篤史; 田充隆; 岩城正宏
    第18回日本医療薬学会年会 2008年
  • ラット肝還流法を用いたジクロフェナクの肝内動態と慢性炎症の影響  [通常講演]
    浦木美里; 松島由佳; 宇野敏志; 川瀬篤史; 岩城正宏
    日本薬剤学会第23年会 2008年
  • CYP2D遺伝的欠損ラットを用いたin vivo-in vitro間の薬物相互作用の予測  [通常講演]
    藤井晃行; 根來真貴子; 石窪未来; 小村 弘; 川瀬篤史; 岩城正宏
    日本薬剤学会第23年会 2008年
  • Alteration on the mRNA Expression of ABC and SLC Transporters in Liver and Intestine of Adjuvant-induced Arthritis Rat  [通常講演]
    Satoshi Uno; Atsushi Kawase; Masahiro Iwaki
    2nd Asian Pacific Regional ISSX Meeting 2008年
  • Differences in Cytochrome P450 and Nuclear Receptor mRNA Levels in Liver and Small Intestine between SD and DA Rats  [通常講演]
    Atsushi Kawase; Akiyuki Fujii; Masahiro Iwaki
    2nd Asian Pacific Regional ISSX Meeting 2008年
  • マイクロRNAによるIRESを介した多重遺伝子発現系における発現制御  [通常講演]
    杉尾久美子; 櫻井文教; 川瀬篤史; 岩城正宏; 川端健二; 水口裕之
    第8回遺伝子・デリバリー研究会 2008年
  • 各種未熟柑橘類エキスによるCYP阻害作用と成分含量との関連  [通常講演]
    藤田 忠; 川瀬篤史; 友廣教道; 増田めぐみ; 松田秀秋; 岩城正宏
    日本薬学会第128年会 2008年
  • トランスポーターを介した薬物相互作用:フラボノイドchrysinのラットおよびマウスbreast cancer resistance protein (Bcrp)に対する影響  [通常講演]
    川瀬篤史; 松本優香子; 羽田野素司; 岩城正宏
    日本薬学会第128年会 2008年
  • 塩酸デクスメデトミジンの肺循環に及ぼす作用  [通常講演]
    稲森雅幸; 塩川泰啓; 中村正人; 川瀬篤史; 岩城正宏; 古賀義久
    第54回麻酔学会 2007年
  • フラボノイドChrysinのマウスBcrp/ABCG2に対する影響  [通常講演]
    川瀬篤史; 松本優香子; 羽田野素司; 岩城正宏
    第2回トランスポーター研究会 2007年
  • Inflammation Impairs Intrinsic Chiral Inversion Activity of "Profen", Nonsteroidal Antiinflammatory Drug  [通常講演]
    Masahiro Iwaki; Misato Uraki; Satoshi Uno; Atsushi Kawase
    Pharmaceutical Sciences World Congress 2007 2007年
  • Effects of CAR on Bilirubin Metabolism in Mouse Collagen-induced Arthritis  [通常講演]
    Atsushi Kawase; You Tsunokuni; Masahiro Iwaki
    Pharmaceutical Sciences World Congress 2007 2007年
  • Substrate depletion assayによる慢性炎症モデルラットにおけるジクロフェナク代謝クリアランスの予測  [通常講演]
    藤井晃行; 宇野敏志; 川瀬篤史; 岩城正宏
    第127年会日本薬学会 2007年
  • 未熟ハッサクの抗アレルギー作用に関する研究  [通常講演]
    友廣教道; 森川 普; 伊藤仁久; 志浦健文; 増田めぐみ; 藤田 忠; 川瀬篤史; 岩城正宏; 我藤 雄; 文室政彦; 佐々木勝昭; 宇都宮直樹; 松田秀秋
    第127年会日本薬学会 2007年
  • 慢性関節炎発症時における核内レセプターの変動とビリルビン代謝に及ぼす影響  [通常講演]
    川瀬篤史; 津國 優; 岩城正宏
    第1回トランスポーター研究会 2006年
  • コラーゲン誘導関節炎マウスでのCAR変動がビリルビン代謝に及ぼす影響  [通常講演]
    川瀬篤史; 津國 優; 岩城正宏
    第21回日本薬物動態学会 2006年
  • 未熟な柑橘類果実の血行改善作用温州ミカン (Citrus unshiu)の血液レオロジー向上作用  [通常講演]
    得永雅士; 藤田 忠; 友廣教道; 増田めぐみ; 安松谷真; 江後絵美; 川瀬篤史; 岩城正宏; 松田秀秋; 佐々木勝昭; 文室政彦; 我藤 雄; 宇都宮直樹
    日本生薬学会第53回年会 2006年
  • アジュバント関節炎ラット肝細胞を用いたイブプロフェンのキラル変換に関する検討  [通常講演]
    宇野敏志; 浦木美里; 川瀬篤史; 岩城正宏
    第21回日本薬物動態学会 2006年
  • 青い柑橘類果実に新規機能性を求めて-青ウンシュウミカンの抗アレルギー作用  [通常講演]
    友廣教道; 志浦健文; 前園知子; 藤田 忠; 岩城正宏; 川瀬篤史; 松田秀秋
    第1回食品薬学シンポジウム 2006年
  • 抗アレルギー作用および美白作用  [通常講演]
    友廣教道; 藤田 忠; 伊藤仁久; 松田秀秋; 川瀬篤史; 岩城正宏; 我藤 雄; 佐々木勝昭; 宇都宮直樹; 久保道徳
    第35回生薬分析シンポジウム 2006年
  • 柑橘類果実の血行改善作用に関する研究  [通常講演]
    友廣教道; 藤田 忠; 伊藤仁久; 松田秀秋; 川瀬篤史; 岩城正宏; 我藤 雄; 佐々木勝昭; 宇都宮直樹; 久保道徳
    第126年会日本薬学会 2006年
  • 未熟な柑橘類果実の血行改善作用  [通常講演]
    友廣教道; 藤田 忠; 伊藤仁久; 松田秀秋; 川瀬篤史; 岩城正宏; 我藤 雄; 佐々木勝昭; 宇都宮直樹; 久保道徳
    第126年会日本薬学会 2006年
  • Alteration in Factors Affecting Drug Disposition during Development of Adjuvant-induced Arthritis in Rats  [通常講演]
    Atsushi Kawase; Satoshi Uno; Kana Yamamoto; Naomi Akitsu; Tomoaki Nagao; Masahiro Iwaki
    第20回年会 JSSX-ISSX合同学会 2005年
  • 柑橘類果実,特にハッサクCitrus hassakuの美白効果に関する研究  [通常講演]
    松田秀秋; 友廣教道; 藤田 忠; 川瀬篤史; 岩城正宏; 我藤 雄; 佐々木勝昭; 宇都宮直樹; 久保道徳
    天然薬物の応用と開発シンポジウム 2005年
  • DNAワクチン療法における抗原の細胞内動態の制御による細胞障害性T細胞活性の増強  [通常講演]
    川瀬篤史; 伊佐次圭子; 的野光洋; 西川元也; 高倉喜信
    第21回日本DDS学会 2005年
  • Improved Antigen Presentation Efficiency by Dendritic Cells with Plasmid DNA Encoding Structure-modified Antigens  [通常講演]
    Keiko Isaji; Makiya Nishikawa; Atsushi Kawase; Ayumi Yamaoka; Yoshinobu Takakura
    5th Globalization of Pharmaceutics Education Network (GPEN) International Graduates Student Meeting 2004年
  • In Vivo Manipulation of Dendritic Cell Migration and Activation to Elicit Immune Response by Polyplex-based DNA Vaccination  [通常講演]
    Atsushi Kawase; Ayumi Yamaoka; Makiya Nishikawa; Yoshinobu Takakura
    5th Globalization of Pharmaceutics Education Network (GPEN) International Graduates Student Meeting 2004年
  • Control of Intracellular Trafficking of Genetically Delivered Antigens in Dendritic Cells for Improved DNA Vaccination  [通常講演]
    Keiko Isaji; Makiya Nishikawa; Atsushi Kawase; Ayumi Yamaoka; Yoshinobu Takakura
    Pharmaceutical Sciences World Congress 2004 2004年
  • Increased Dendritic Cell Migration to the Vaccination Site and Enhanced Immune Response by Polyplex-based DNA Vaccine  [通常講演]
    Atsushi Kawase; Ayumi Yamaoka; Makiya Nishikawa; Yoshinobu Takakura
    Pharmaceutical Sciences World Congress 2004 2004年
  • メチル化BSAを利用したプラスミドDNAによる抗原特異的抗体産生の増大  [通常講演]
    伊佐次圭子; 川瀬篤史; 山岡あゆみ; 西川元也; 高倉喜信
    第13回アンチセンスシンポジウム 2003年
  • カチオン性高分子/プラスミドDNA複合体化によるDNAワクチン効果の増強およびそのメカニズム  [通常講演]
    川瀬篤史; 伊佐次圭子; 小林直樹; 西川元也; 高倉喜信
    日本DDS学会第19年会 2003年
  • ハイドロダイナミクス (Hydrodynamics)法による肝細胞への効率的遺伝子デリバリーメカニズム  [通常講演]
    小林直樹; 川瀬篤史; 西川元也; 高倉喜信
    日本DDS学会第19年会 2003年
  • カチオン性高分子キャリアーを用いたプラスミドDNA複合体化によるDNAワクチン効果の制御  [通常講演]
    川瀬篤史; 伊佐次圭子; 小林直樹; 西川元也; 高倉喜信
    日本薬剤学会第18年会 2003年
  • Control of Disposition Characteristics of Plasmid DNA after Local Administration by Complexation with Cationic Macromolecules  [通常講演]
    Atsushi Kawase; Naoki Kobayashi; Kiyoshi Yamaoka; Yoshinobu Takakura
    29th Annual Meeting and Exposition of the Controlled Release Society 2002年
  • メチル化BSA複合体化によるプラスミドDNAの局所投与時の動態および免疫応答の制御  [通常講演]
    川瀬篤史; 小林直樹; 高倉喜信
    遺伝子・デリバリー研究会第2回シンポジウム 2002年
  • メチル化BSA/プラスミドDNA複合体の筋肉内投与の体内動態と遺伝子発現  [通常講演]
    川瀬篤史; 山岡 清; 高倉喜信
    日本薬学会第122年会 2002年
  • プラスミドDNAの局所投与時の体内動態と遺伝子発現機構に関する検討  [通常講演]
    川瀬篤史; 山岡 清; 高倉喜信
    日本薬剤学会第16年会 2001年

MISC

受賞

  • 2016年10月 日本薬局学会 日本薬局学会ポスター優秀演題賞
     
    受賞者: 川瀬篤史
  • 2014年12月 日本薬剤学会 Global Education Seminar Presentation Award
     
    受賞者: 川瀬篤史
  • 2014年01月 日本薬学会 日本薬学会近畿支部奨励賞
     
    受賞者: 川瀬篤史
  • 2002年05月 遺伝子・デリバリー研究会 遺伝子・デリバリー研究会奨励賞

共同研究・競争的資金等の研究課題

  • トランスポーター周辺タンパク質標的型ペプチドを用いた抗がん薬デリバリー効率の改善
    独立行政法人 日本学術振興会 科学研究費助成(基盤研究(C)):
    研究期間 : 2021年04月 -2024年03月 
    代表者 : 川瀬篤史
  • トランスポーター周辺タンパク質は抗がん薬多剤耐性克服のターゲットとなり得るか?
    独立行政法人 日本学術振興会 科学研究費助成(基盤研究(C)):
    研究期間 : 2018年04月 -2021年03月 
    代表者 : 川瀬 篤史
  • 特異体質性肝障害にアシルCoAチオエステル中間代謝物は関与しているか?
    独立行政法人 日本学術振興会:科学研究費助成(基盤研究(C))
    研究期間 : 2017年04月 -2020年03月 
    代表者 : 岩城正宏
  • 標的プロテオミクス法による炎症時のトランスポーター機能および薬物動態解析
    近畿大学 学内研究助成金(奨励)
    研究期間 : 2017年04月 -2018年03月
  • ERMタンパク質リン酸化状態およびトランスポーター機能に対する炎症因子の影響
    独立行政法人 日本学術振興会:科学研究費助成(若手研究 (B))
    研究期間 : 2016年04月 -2018年03月 
    代表者 : 川瀬篤史
  • 炎症時におけるERMタンパク質変動とトランスポーター機能との関連
    独立行政法人 日本学術振興会:科学研究費助成(若手研究 (B))
    研究期間 : 2014年04月 -2016年03月 
    代表者 : 川瀬篤史
  • 種々の炎症モデルにおけるERMタンパク質およびトランスポーター機能に対する影響
    近畿大学 学内研究助成金(奨励)
    研究期間 : 2014年04月 -2015年03月
  • アデノウイルスベクターを利用した特異体質性肝障害機序の解明
    公益財団法人 上原記念生命科学財団:研究奨励金
    研究期間 : 2012年04月 -2013年03月 
    代表者 : 川瀬篤史
  • 反応性代謝物を介する肝障害発現に関与する機能タンパク質の解明
    独立行政法人 日本学術振興会:科学研究費助成(基盤研究(C))
    研究期間 : 2011年04月 -2013年03月 
    代表者 : 岩城正宏
  • アデノウイルスベクターを利用したNSAIDsの肝毒性発現機構の解明
    近畿大学 学内研究助成金(奨励)
    研究期間 : 2010年04月 -2011年03月
  • 日本学術振興会:科学研究費助成事業 若手研究(A)
    研究期間 : 2008年 -2010年 
    代表者 : 櫻井 文教; 水口 裕之; 川端 健二; 形山 和史; 田代 克久; 近藤 昌夫; 八木 清仁; 中村 紳一朗; 川瀬 篤史; 岩城 正宏; 早川 尭夫; 藤原 俊義; 鈴木 孝幸; 杉尾 久美子; 清水 かほり; 富田 恭子
     
    本研究では、アデノウイルス(Ad)ベクターに、マイクロRNA(miRNA)による遺伝子発現制御システムを搭載することにより、miRNAの発現依存的に遺伝子の発現を制御可能な安全性の高いAdベクターを開発することに成功した。具体的には、(1)肝臓もしくは脾臓における導入遺伝子の発現を抑制可能なAdベクター、(2)Ad遺伝子の非特異的な発現を抑制可能なAdベクター、(3)正常細胞での増殖を大きく抑制した制限増殖型Adを開発した。
  • フラボノイドまたはフラノクマリンによるBCRP阻害効果と臓器選択的薬物送達への応用
    近畿大学 学内研究助成金(奨励)
    研究期間 : 2007年04月 -2008年03月

委員歴

  • 2022年 - 現在   日本毒性学会   評議員
  • 2008年 - 現在   トランスポーター研究会   幹事
  • 2020年09月 - 2021年10月   第71回 日本薬学会関西支部 総会・大会 実行委員
  • 2012年04月 - 2016年03月   日本薬剤学会英語セミナー西地区委員
  • 2008年09月 - 2009年10月   第59回日本薬学会近畿支部 総会・大会 実行委員
  • 2005年09月 - 2006年08月   第13回薬と医療シンポジウム実行委員

担当経験のある科目

  • 薬物動態学近畿大学薬学部
  • 総合演習2近畿大学薬学部
  • 総合演習1近畿大学薬学部
  • 基礎ゼミ近畿大学薬学部
  • 生物学入門近畿大学薬学部
  • 基礎生物学近畿大学薬学部
  • 生命の科学近畿大学
  • 生物学英語近畿大学薬学部
  • 薬物速度論近畿大学薬学部

その他

  • 2017年04月 - 2017年04月  標的プロテオミクス法による炎症時のトランスポーター機能および薬物動態解析 
    近畿大学学内奨励研究助成金 SR03
  • 2015年04月 - 2015年04月  アクティブ・ラーニングを取り入れた双方向授業の導入と評価法の構築―学生参加型学習推進のための問題抽出とその対策 
    近畿大学学内研究助成金 21世紀教育開発奨励金【教育推進研究助成金】KS01
  • 2014年04月 - 2014年04月  種々の炎症モデルにおけるERMタンパク質およびトランスポーター機能に対する影響 
    近畿大学学内奨励研究助成金 SR04
  • 2010年04月 - 2010年04月  アデノウイルスベクターを利用したNSAIDSの肝毒性機構の解明 
    近畿大学学内奨励研究助成金 SR03
  • 2007年04月 - 2007年04月  フラボノイドまたはフラノクマリンによるBCRP阻害効果と臓器選択的薬物送達への応用 
    近畿大学学内奨励研究助成金 GS05

その他のリンク

researchmap



Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.